Oct2	B-protein
transactivation	O
from	O
a	O
remote	B-DNA
enhancer	I-DNA
position	I-DNA
requires	O
a	O
B-cell-restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte-specific	B-protein
transcription	I-protein
factor	I-protein
Oct2	B-protein
could	O
efficiently	O
activate	O
a	O
promoter	B-DNA
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	B-protein
expression	O
was	O
unable	O
to	O
stimulate	O
a	O
multimerized	B-DNA
octamer	I-DNA
enhancer	I-DNA
element	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	B-protein
isoforms	I-protein
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	B-DNA
enhancer	I-DNA
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
and	O
a	O
B-cell	B-cell_line
line	I-cell_line
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	B-protein
isoforms	I-protein
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell-specific	B-protein
cofactor	I-protein
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	B-protein
or	O
the	O
Oct2	B-protein
protein	I-protein
in	O
Oct2	B-protein
-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy-terminal	B-protein
domain	I-protein
of	O
Oct2	B-protein
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	B-protein
protein	I-protein
,	O
which	O
by	O
itself	O
was	O
unable	O
to	O
stimulate	O
from	O
a	O
remote	O
position	O
.	O

The	O
glutamine-rich	B-protein
activation	I-protein
domain	I-protein
present	O
in	O
the	O
amino-terminal	B-protein
portion	I-protein
of	I-protein
Oct2	I-protein
and	O
the	O
POU	B-protein
domain	I-protein
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

MoLEcuLar	NULL
Anp	NULL
CELLULAR	NULL
BroroGYy	NULL
,	NULL
July	NULL
1992	NULL
,	NULL
p.	NULL
3107-3116	NULL
0270-7306/92/073107-10	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
Â©	NULL
1992	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

12	NULL
,	NULL
No	NULL
.	NULL

7	NULL
Oct2	NULL
Transactivation	NULL
from	NULL
a	NULL
Remote	NULL
Enhancer	NULL
Position	NULL
Requires	NULL
a	NULL
B-Cell-Restricted	NULL
Activity	NULL
A.	NULL
ANNWEILER	NULL
,	NULL
'	NULL
M.	NULL
MULLER-IMMERGLUCK	NULL
,	NULL
ano	NULL
T.	NULL
WIRTH'*	NULL
Zentrum	NULL
fiir	NULL
Molekulare	NULL
Biologie	NULL
Heidelberg	NULL
,	NULL
Im	NULL
Neuenheimer	NULL
Feld	NULL
282	NULL
,	NULL
D-6900	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
,	NULL
and	NULL
Institut	NULL
fiir	NULL
Molekularbiologie	NULL
II	NULL
der	NULL
Universitit	NULL
Zurich	NULL
,	NULL
CH	NULL
8057	NULL
Zurich	NULL
,	NULL
Switzerland	NULL
``	NULL
Received	NULL
16	NULL
January	NULL
1992/Accepted	NULL
17	NULL
April	NULL
1992	NULL
Previous	NULL
cotransfection	NULL
experiments	NULL
had	NULL
demonstrated	NULL
that	NULL
ectopic	NULL
expression	NULL
of	NULL
the	NULL
lymphocyte-specific	NULL
transcription	NULL
factor	NULL
Oct2	NULL
could	NULL
efficiently	NULL
activate	NULL
a	NULL
promoter	NULL
containing	NULL
an	NULL
octamer	NULL
motif	NULL
.	NULL

Oct2	NULL
expression	NULL
was	NULL
unable	NULL
to	NULL
stimulate	NULL
a	NULL
multimerized	NULL
octamer	NULL
enhancer	NULL
element	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
however	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
a	NULL
variety	NULL
of	NULL
Oct2	NULL
isoforms	NULL
generated	NULL
by	NULL
alternative	NULL
splicing	NULL
for	NULL
the	NULL
capability	NULL
to	NULL
activate	NULL
an	NULL
octamer	NULL
enhancer	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
and	NULL
a	NULL
B-cell	NULL
line	NULL
.	NULL

Our	NULL
analyses	NULL
show	NULL
that	NULL
several	NULL
Oct2	NULL
isoforms	NULL
can	NULL
stimulate	NULL
from	NULL
a	NULL
remote	NULL
position	NULL
but	NULL
that	NULL
this	NULL
stimulation	NULL
is	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
the	NULL
involvement	NULL
of	NULL
either	NULL
a	NULL
B-cell-specific	NULL
cofactor	NULL
or	NULL
a	NULL
specific	NULL
modification	NULL
of	NULL
a	NULL
cofactor	NULL
or	NULL
the	NULL
Oct2	NULL
protein	NULL
in	NULL
Oct2-mediated	NULL
enhancer	NULL
activation	NULL
.	NULL

Mutational	NULL
analyses	NULL
indicate	NULL
that	NULL
the	NULL
carboxy-terminal	NULL
domain	NULL
of	NULL
Oct2	NULL
is	NULL
critical	NULL
for	NULL
enhancer	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
domain	NULL
conferred	NULL
enhancing	NULL
activity	NULL
when	NULL
fused	NULL
to	NULL
the	NULL
Oct1	NULL
protein	NULL
,	NULL
which	NULL
by	NULL
itself	NULL
was	NULL
unable	NULL
to	NULL
stimulate	NULL
from	NULL
a	NULL
remote	NULL
position	NULL
.	NULL

The	NULL
glutamine-rich	NULL
activation	NULL
domain	NULL
present	NULL
in	NULL
the	NULL
amino-terminal	NULL
portion	NULL
of	NULL
Oct2	NULL
and	NULL
the	NULL
POU	NULL
domain	NULL
contribute	NULL
only	NULL
marginally	NULL
to	NULL
the	NULL
transactivation	NULL
function	NULL
from	NULL
a	NULL
distal	NULL
position	NULL
.	NULL

Regulation	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
higher	NULL
eucaryotes	NULL
is	NULL
governed	NULL
both	NULL
by	NULL
promoter	NULL
elements	NULL
localized	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
gene	NULL
and	NULL
additional	NULL
enhancer	NULL
elements	NULL
which	NULL
can	NULL
function	NULL
over	NULL
long	NULL
distances	NULL
.	NULL

These	NULL
cis-acting	NULL
elements	NULL
interact	NULL
with	NULL
a	NULL
diverse	NULL
set	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
often	NULL
show	NULL
a	NULL
preference	NULL
for	NULL
either	NULL
promoter	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
Spl	NULL
or	NULL
CCAAT-binding	NULL
transcription	NULL
factor/nuclear	NULL
factor	NULL
I	NULL
)	NULL
or	NULL
enhancer	NULL
elements	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
factors	NULL
interacting	NULL
with	NULL
the	NULL
E-box	NULL
motifs	NULL
in	NULL
immunoglobulin	NULL
enhancers	NULL
or	NULL
the	NULL
bovine	NULL
papillomavirus	NULL
E2	NULL
transactivator	NULL
)	NULL
(	NULL
12	NULL
,	NULL
23	NULL
)	NULL
.	NULL

However	NULL
,	NULL
several	NULL
transcription	NULL
factors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
function	NULL
from	NULL
both	NULL
proximal	NULL
promoter	NULL
and	NULL
remote	NULL
enhancer	NULL
positions	NULL
(	NULL
2	NULL
,	NULL
30	NULL
,	NULL
42	NULL
)	NULL
.	NULL

The	NULL
octamer	NULL
motif	NULL
ATGCAAAT	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
immunoglobulin	NULL
gene	NULL
expression	NULL
.	NULL

This	NULL
site	NULL
is	NULL
conserved	NULL
in	NULL
the	NULL
heavy-chain	NULL
enhancer	NULL
elements	NULL
as	NULL
well	NULL
as	NULL
in	NULL
virtually	NULL
all	NULL
heavy-	NULL
and	NULL
light-chain	NULL
promoter	NULL
elements	NULL
(	NULL
7	NULL
,	NULL
29	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
found	NULL
in	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
other	NULL
genes	NULL
specifically	NULL
expressed	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
,	NULL
and	NULL
slightly	NULL
aberrant	NULL
octamer	NULL
motifs	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
the	NULL
intronic	NULL
enhancer	NULL
of	NULL
the	NULL
immunoglobulin	NULL
x	NULL
light-chain	NULL
gene	NULL
(	NULL
3	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
is	NULL
present	NULL
in	NULL
the	NULL
regulatory	NULL
regions	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
genes	NULL
that	NULL
do	NULL
not	NULL
show	NULL
B-cell-restricted	NULL
expression	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Mutational	NULL
analyses	NULL
have	NULL
confirmed	NULL
the	NULL
importance	NULL
of	NULL
this	NULL
motif	NULL
for	NULL
specific	NULL
promoter	NULL
and	NULL
enhancer	NULL
functions	NULL
(	NULL
10	NULL
,	NULL
19	NULL
,	NULL
21	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Several	NULL
genes	NULL
that	NULL
encode	NULL
octamer-binding	NULL
proteins	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
and	NULL
all	NULL
these	NULL
proteins	NULL
show	NULL
homology	NULL
in	NULL
the	NULL
domain	NULL
responsible	NULL
for	NULL
specific	NULL
DNA	NULL
binding	NULL
,	NULL
the	NULL
so-called	NULL
POU	NULL
domain	NULL
(	NULL
1a	NULL
,	NULL
24	NULL
,	NULL
27	NULL
,	NULL
31	NULL
,	NULL
34	NULL
,	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

The	NULL
POU	NULL
domain	NULL
consists	NULL
of	NULL
a	NULL
conserved	NULL
POU-specific	NULL
(	NULL
75	NULL
to	NULL
80	NULL
amino	NULL
acids	NULL
long	NULL
)	NULL
subdomain	NULL
and	NULL
a	NULL
POU-homeo	NULL
(	NULL
60	NULL
amino	NULL
acids	NULL
long	NULL
)	NULL
subdomain	NULL
which	NULL
are	NULL
separated	NULL
by	NULL
a	NULL
less	NULL
well-conserved	NULL
linker	NULL
of	NULL
variable	NULL
length	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
lymphoid	NULL
cell-specific	NULL
functions	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
have	NULL
been	NULL
attributed	NULL
to	NULL
the	NULL
Oct2	NULL
transcription	NULL
factor	NULL
,	NULL
a	NULL
lymphoid	NULL
cell-specific	NULL
protein	NULL
which	NULL
is	NULL
coexpressed	NULL
in	NULL
B	NULL
cells	NULL
with	NULL
the	NULL
ubiquitous	NULL
Octl	NULL
protein	NULL
(	NULL
20	NULL
,	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

Mouse	NULL
and	NULL
human	NULL
B	NULL
cells	NULL
express	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

3107	NULL
multiple	NULL
Oct2	NULL
isoforms	NULL
which	NULL
arise	NULL
from	NULL
a	NULL
singular	NULL
Oct2	NULL
gene	NULL
by	NULL
an	NULL
alternative	NULL
splicing	NULL
mechanism	NULL
(	NULL
43	NULL
)	NULL
.	NULL

These	NULL
Oct2	NULL
isoforms	NULL
all	NULL
contain	NULL
the	NULL
conserved	NULL
POU	NULL
domain	NULL
,	NULL
and	NULL
they	NULL
are	NULL
coexpressed	NULL
at	NULL
all	NULL
stages	NULL
of	NULL
B-cell	NULL
development	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Ectopic	NULL
expression	NULL
of	NULL
Oct2	NULL
in	NULL
HeLa	NULL
cells	NULL
or	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
activate	NULL
a	NULL
promoter	NULL
containing	NULL
an	NULL
octamer	NULL
motif	NULL
(	NULL
9	NULL
,	NULL
24	NULL
,	NULL
25	NULL
,	NULL
40	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Those	NULL
experiments	NULL
identified	NULL
two	NULL
regions	NULL
in	NULL
the	NULL
Oct2	NULL
protein	NULL
contributing	NULL
to	NULL
full	NULL
transactivating	NULL
potential	NULL
,	NULL
a	NULL
glutamine-rich	NULL
domain	NULL
in	NULL
the	NULL
amino	NULL
terminus	NULL
and	NULL
a	NULL
region	NULL
carboxy	NULL
terminal	NULL
to	NULL
the	NULL
POU	NULL
domain	NULL
(	NULL
9	NULL
,	NULL
25	NULL
,	NULL
40	NULL
)	NULL
.	NULL

In	NULL
those	NULL
experiments	NULL
,	NULL
a	NULL
multimerized	NULL
octamer	NULL
motif	NULL
functioning	NULL
as	NULL
an	NULL
efficient	NULL
B-cell-specific	NULL
enhancer	NULL
could	NULL
not	NULL
be	NULL
stimulated	NULL
in	NULL
HeLa	NULL
cells	NULL
by	NULL
coexpression	NULL
of	NULL
Oct2	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Two	NULL
alternate	NULL
hypotheses	NULL
could	NULL
explain	NULL
this	NULL
result	NULL
:	NULL
(	NULL
i	NULL
)	NULL
as	NULL
only	NULL
a	NULL
single	NULL
Oct2	NULL
isoform	NULL
had	NULL
been	NULL
tested	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
that	NULL
one	NULL
of	NULL
the	NULL
other	NULL
recently	NULL
identified	NULL
variants	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
enhancer	NULL
transactivation	NULL
;	NULL
(	NULL
ii	NULL
)	NULL
alternatively	NULL
,	NULL
Oct2	NULL
could	NULL
require	NULL
a	NULL
B-cell-specific	NULL
component	NULL
for	NULL
enhancer	NULL
activation	NULL
that	NULL
is	NULL
missing	NULL
in	NULL
the	NULL
HeLa	NULL
cell	NULL
line	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
these	NULL
two	NULL
models	NULL
experimentally	NULL
by	NULL
cotransfecting	NULL
a	NULL
variety	NULL
of	NULL
Oct2	NULL
isoforms	NULL
with	NULL
a	NULL
reporter	NULL
bearing	NULL
multimerized	NULL
octamer	NULL
motifs	NULL
as	NULL
enhancer	NULL
.	NULL

Both	NULL
nonlymphoid	NULL
cells	NULL
and	NULL
a	NULL
B-cell	NULL
line	NULL
containing	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
endogenous	NULL
Oct2	NULL
were	NULL
transfected	NULL
.	NULL

We	NULL
show	NULL
that	NULL
the	NULL
enhancer	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
several	NULL
Oct2	NULL
isoforms	NULL
but	NULL
that	NULL
this	NULL
activation	NULL
can	NULL
be	NULL
achieved	NULL
only	NULL
in	NULL
a	NULL
B-cell	NULL
back-ground	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
fusion	NULL
protein	NULL
of	NULL
Oct2	NULL
with	NULL
the	NULL
very	NULL
strong	NULL
acidic	NULL
transactivation	NULL
domain	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
VP16	NULL
protein	NULL
can	NULL
readily	NULL
stimulate	NULL
the	NULL
enhancer	NULL
in	NULL
non-B	NULL
cells	NULL
,	NULL
too	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
analyses	NULL
indicate	NULL
that	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
Oct2	NULL
is	NULL
crucial	NULL
for	NULL
efficient	NULL
enhancer	NULL
transactivation	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Plasmid	NULL
constructions	NULL
.	NULL

The	NULL
pCL	NULL
plasmid	NULL
containing	NULL
the	NULL
chicken	NULL
lysozyme	NULL
promoter	NULL
from	NULL
-579	NULL
to	NULL
+15	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
was	NULL
supplied	NULL
by	NULL
A.	NULL
Hecht	NULL
.	NULL

The	NULL
six	NULL
copies	NULL
3108	NULL
ANNWEILER	NULL
ET	NULL
AL	NULL
.	NULL

of	NULL
either	NULL
the	NULL
wild-type	NULL
or	NULL
mutated	NULL
enhancer	NULL
fragment	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
10	NULL
)	NULL
.	NULL

They	NULL
were	NULL
inserted	NULL
into	NULL
a	NULL
unique	NULL
Smal	NULL
site	NULL
downstream	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

All	NULL
inserts	NULL
had	NULL
the	NULL
same	NULL
orientations	NULL
.	NULL

The	NULL
octamer	NULL
promoter	NULL
constructs	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
pTATA	NULL
plasmid	NULL
(	NULL
obtained	NULL
from	NULL
A.	NULL
Hecht	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
from	NULL
-38	NULL
to	NULL
+52	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

The	NULL
wild-type	NULL
octamer	NULL
motif	NULL
ATGCAAAT	NULL
and	NULL
a	NULL
motif	NULL
with	NULL
a	NULL
point	NULL
mutation	NULL
,	NULL
ATGAAAAT	NULL
,	NULL
were	NULL
used	NULL
.	NULL

Expression	NULL
vectors	NULL
carrying	NULL
the	NULL
Oct2	NULL
isoforms	NULL
were	NULL
the	NULL
described	NULL
cytomegalovirus	NULL
expression	NULL
constructs	NULL
(	NULL
43	NULL
)	NULL
,	NULL
pGD	NULL
retroviral	NULL
vectors	NULL
(	NULL
4	NULL
)	NULL
,	NULL
or	NULL
Rous	NULL
sarcoma	NULL
virus-based	NULL
expression	NULL
vectors	NULL
(	NULL
vector	NULL
obtained	NULL
from	NULL
R.	NULL
Renkawitz	NULL
)	NULL
.	NULL

The	NULL
different	NULL
expression	NULL
vectors	NULL
yielded	NULL
identical	NULL
results	NULL
and	NULL
were	NULL
used	NULL
interchangeably	NULL
.	NULL

The	NULL
Oct2	NULL
deletion	NULL
mutants	NULL
and	NULL
the	NULL
Oct1-Oct2	NULL
fusion	NULL
proteins	NULL
have	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
9	NULL
,	NULL
25	NULL
,	NULL
40	NULL
)	NULL
.	NULL

The	NULL
Oct2-VP16	NULL
fusion	NULL
was	NULL
constructed	NULL
as	NULL
follows	NULL
.	NULL

The	NULL
VP16	NULL
transactivation	NULL
domain	NULL
was	NULL
isolated	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
amplification	NULL
from	NULL
the	NULL
murine	NULL
sarcoma	NULL
virus	NULL
VP16	NULL
expression	NULL
plasmid	NULL
.	NULL

The	NULL
primers	NULL
used	NULL
were	NULL
5	NULL
'	NULL
CCATCGATACACACGCGCAGACTGTCGACG	NULL
3	NULL
'	NULL
(	NULL
positions	NULL
2054	NULL
to	NULL
2073	NULL
)	NULL
and	NULL
5Â°	NULL
CGTCTAGAACCCACCGTACT	NULL
CGTCAATTCC	NULL
3	NULL
'	NULL
(	NULL
positions	NULL
2287	NULL
to	NULL
2307	NULL
)	NULL
(	NULL
28	NULL
)	NULL
.	NULL

The	NULL
amplified	NULL
fragment	NULL
corresponds	NULL
to	NULL
amino	NULL
acids	NULL
406	NULL
to	NULL
488	NULL
of	NULL
the	NULL
VP16	NULL
protein	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
cut	NULL
with	NULL
Clal	NULL
and	NULL
Xbal	NULL
,	NULL
filled	NULL
in	NULL
with	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
,	NULL
and	NULL
inserted	NULL
into	NULL
the	NULL
filled-in	NULL
EcoRI	NULL
site	NULL
of	NULL
a	NULL
pBluescript	NULL
plasmid	NULL
containing	NULL
the	NULL
Oct2.6	NULL
isoform	NULL
which	NULL
had	NULL
the	NULL
C	NULL
terminus	NULL
just	NULL
downstream	NULL
of	NULL
the	NULL
POU	NULL
domain	NULL
deleted	NULL
(	NULL
partial	NULL
Smal	NULL
dele-tion	NULL
)	NULL
.	NULL

The	NULL
fusion	NULL
was	NULL
then	NULL
transferred	NULL
to	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
expression	NULL
vector	NULL
.	NULL

Cell	NULL
culture	NULL
and	NULL
DNA	NULL
transfections	NULL
.	NULL

$	NULL
194	NULL
cells	NULL
were	NULL
kept	NULL
in	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
and	NULL
transfected	NULL
with	NULL
DEAE-dextran	NULL
as	NULL
described	NULL
elsewhere	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Conditions	NULL
for	NULL
culturing	NULL
and	NULL
transfection	NULL
of	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
(	NULL
43	NULL
)	NULL
and	NULL
chicken	NULL
HD11	NULL
macrophages	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
for	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
prepared	NULL
by	NULL
freeze-thaw	NULL
lysis	NULL
in	NULL
buffer	NULL
C	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Conditions	NULL
for	NULL
band	NULL
shift	NULL
assays	NULL
with	NULL
the	NULL
cleared	NULL
lysates	NULL
and	NULL
the	NULL
octamer	NULL
fragment	NULL
from	NULL
the	NULL
heavy-chain	NULL
enhancer	NULL
were	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Whole-cell	NULL
extracts	NULL
for	NULL
enzyme	NULL
assays	NULL
were	NULL
obtained	NULL
by	NULL
freeze-thaw	NULL
lysis	NULL
in	NULL
0.1	NULL
M	NULL
potassium	NULL
phosphate-1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
pH	NULL
7.8	NULL
.	NULL

Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
by	NULL
using	NULL
a	NULL
Berthold	NULL
Lumat	NULL
9501	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
B-galactosidase	NULL
activity	NULL
was	NULL
performed	NULL
by	NULL
following	NULL
standard	NULL
protocols	NULL
(	NULL
14	NULL
)	NULL
.	NULL

All	NULL
luciferase	NULL
expression	NULL
values	NULL
were	NULL
corrected	NULL
for	NULL
B-galactosidase	NULL
enzyme	NULL
levels	NULL
.	NULL

RESULTS	NULL
Oct2	NULL
isoforms	NULL
can	NULL
activate	NULL
an	NULL
octamer-containing	NULL
enhancer	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

It	NULL
had	NULL
been	NULL
shown	NULL
previously	NULL
that	NULL
six	NULL
copies	NULL
of	NULL
a	NULL
short	NULL
fragment	NULL
from	NULL
the	NULL
mouse	NULL
intronic	NULL
heavy-chain	NULL
enhancer	NULL
encompassing	NULL
the	NULL
octamer	NULL
motif	NULL
and	NULL
the	NULL
E4	NULL
motif	NULL
can	NULL
function	NULL
as	NULL
an	NULL
efficient	NULL
B-cell-specific	NULL
enhancer	NULL
element	NULL
(	NULL
10	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
generated	NULL
reporter	NULL
plasmids	NULL
bearing	NULL
this	NULL
multimerized	NULL
fragment	NULL
about	NULL
2	NULL
kb	NULL
downstream	NULL
of	NULL
the	NULL
transcriptional	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

We	NULL
chose	NULL
the	NULL
chicken	NULL
lysozyme	NULL
promoter	NULL
as	NULL
the	NULL
proximal	NULL
promoter	NULL
element	NULL
because	NULL
it	NULL
showed	NULL
fairly	NULL
low	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
on	NULL
its	NULL
own	NULL
(	NULL
about	NULL
threefold	NULL
higher	NULL
than	NULL
a	NULL
reporter	NULL
construct	NULL
containing	NULL
only	NULL
a	NULL
TATA	NULL
box	NULL
;	NULL
unpublished	NULL
obser-vations	NULL
)	NULL
,	NULL
and	NULL
it	NULL
was	NULL
stimulated	NULL
to	NULL
high	NULL
levels	NULL
of	NULL
activity	NULL
by	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

the	NULL
multimerized	NULL
wild-type	NULL
enhancer	NULL
fragments	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

A	NULL
reporter	NULL
construct	NULL
bearing	NULL
the	NULL
B-galactosidase	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
a	NULL
strong	NULL
enhancer	NULL
(	NULL
cytomegalovirus	NULL
lacZ	NULL
or	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
lacZ	NULL
)	NULL
was	NULL
included	NULL
in	NULL
all	NULL
transfections	NULL
.	NULL

All	NULL
luciferase	NULL
expression	NULL
values	NULL
were	NULL
normalized	NULL
for	NULL
B-galactosidase	NULL
activity	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
extracts	NULL
.	NULL

Consistent	NULL
with	NULL
previous	NULL
findings	NULL
,	NULL
the	NULL
enhancer	NULL
activity	NULL
was	NULL
observed	NULL
only	NULL
in	NULL
the	NULL
$	NULL
194	NULL
plasmacytoma	NULL
cell	NULL
line	NULL
and	NULL
not	NULL
in	NULL
fibroblasts	NULL
or	NULL
in	NULL
a	NULL
chicken	NULL
macrophage	NULL
cell	NULL
line	NULL
,	NULL
in	NULL
which	NULL
the	NULL
promoter	NULL
showed	NULL
significantly	NULL
higher	NULL
background	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
previous	NULL
observations	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
wE4	NULL
motif	NULL
reduced	NULL
enhancer	NULL
activity	NULL
only	NULL
marginally	NULL
,	NULL
whereas	NULL
the	NULL
octamer	NULL
mutation	NULL
led	NULL
to	NULL
a	NULL
strong	NULL
reduction	NULL
of	NULL
enhancer	NULL
activity	NULL
,	NULL
confirming	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
for	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
enhancer	NULL
element	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
residual	NULL
enhancer	NULL
activity	NULL
was	NULL
still	NULL
B	NULL
cell	NULL
specific	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
10	NULL
)	NULL
.	NULL

A	NULL
double	NULL
mutation	NULL
of	NULL
the	NULL
E4	NULL
motif	NULL
and	NULL
the	NULL
octamer	NULL
site	NULL
abolished	NULL
this	NULL
residual	NULL
enhancer	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
(	NULL
10	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
any	NULL
of	NULL
the	NULL
Oct2	NULL
isoforms	NULL
could	NULL
activate	NULL
the	NULL
enhancer	NULL
,	NULL
we	NULL
performed	NULL
cotransfections	NULL
with	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
.	NULL

However	NULL
,	NULL
none	NULL
of	NULL
the	NULL
isoforms	NULL
was	NULL
capable	NULL
of	NULL
stimulating	NULL
the	NULL
enhancer	NULL
to	NULL
a	NULL
measurable	NULL
level	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
fusion	NULL
protein	NULL
encompassing	NULL
the	NULL
amino	NULL
terminus	NULL
and	NULL
the	NULL
POU	NULL
domain	NULL
of	NULL
Oct2	NULL
and	NULL
the	NULL
transactivating	NULL
domain	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
VP16	NULL
transactivator	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
and	NULL
this	NULL
construct	NULL
activated	NULL
the	NULL
wild-type	NULL
enhancer	NULL
about	NULL
20-fold	NULL
in	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
.	NULL

Similarly	NULL
,	NULL
only	NULL
this	NULL
Oct2-VP16	NULL
fusion	NULL
could	NULL
activate	NULL
the	NULL
enhancer	NULL
in	NULL
a	NULL
chicken	NULL
macrophage	NULL
cell	NULL
line	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
showed	NULL
that	NULL
the	NULL
multimerized	NULL
octamer	NULL
enhancer	NULL
could	NULL
be	NULL
activated	NULL
in	NULL
non-B	NULL
cells	NULL
but	NULL
that	NULL
Oct2	NULL
alone	NULL
was	NULL
unable	NULL
to	NULL
do	NULL
so	NULL
.	NULL

From	NULL
these	NULL
results	NULL
,	NULL
the	NULL
second	NULL
of	NULL
the	NULL
models	NULL
,	NULL
namely	NULL
,	NULL
the	NULL
involvement	NULL
of	NULL
a	NULL
B-cell-specific	NULL
activity	NULL
required	NULL
for	NULL
Oct2	NULL
function	NULL
from	NULL
a	NULL
remote	NULL
position	NULL
,	NULL
became	NULL
increasingly	NULL
at-tractive	NULL
.	NULL

To	NULL
test	NULL
this	NULL
idea	NULL
,	NULL
we	NULL
cotransfected	NULL
the	NULL
various	NULL
reporter	NULL
constructs	NULL
with	NULL
the	NULL
Oct2	NULL
expression	NULL
vectors	NULL
into	NULL
the	NULL
mouse	NULL
$	NULL
194	NULL
plasmacytoma	NULL
cell	NULL
line	NULL
,	NULL
which	NULL
is	NULL
characterized	NULL
by	NULL
low	NULL
levels	NULL
of	NULL
endogenous	NULL
Oct2	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Despite	NULL
these	NULL
low	NULL
levels	NULL
of	NULL
endogenous	NULL
Oct2	NULL
,	NULL
the	NULL
multimerized	NULL
enhancer	NULL
fragment	NULL
yielded	NULL
already	NULL
significant	NULL
octamer-dependent	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Cotransfection	NULL
with	NULL
the	NULL
Oct2	NULL
expression	NULL
vectors	NULL
resulted	NULL
in	NULL
a	NULL
clear	NULL
stimulation	NULL
of	NULL
this	NULL
baseline	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

There	NULL
was	NULL
considerable	NULL
variation	NULL
in	NULL
the	NULL
transactivation	NULL
potentials	NULL
of	NULL
various	NULL
Oct2	NULL
isoforms	NULL
.	NULL

Three	NULL
of	NULL
the	NULL
isoforms	NULL
(	NULL
Oct2.1	NULL
,	NULL
Oct2.2	NULL
,	NULL
and	NULL
Oct2.6	NULL
)	NULL
gave	NULL
a	NULL
clear	NULL
stimulation	NULL
,	NULL
whereas	NULL
the	NULL
others	NULL
(	NULL
Oct2.4	NULL
,	NULL
Oct2.5	NULL
,	NULL
and	NULL
Oct2.3	NULL
)	NULL
had	NULL
little	NULL
effect	NULL
or	NULL
even	NULL
led	NULL
to	NULL
a	NULL
slight	NULL
reduction	NULL
of	NULL
the	NULL
baseline	NULL
activity	NULL
.	NULL

This	NULL
variation	NULL
was	NULL
observed	NULL
over	NULL
a	NULL
range	NULL
of	NULL
expression	NULL
vector	NULL
concentrations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
analysis	NULL
of	NULL
Oct2	NULL
proteins	NULL
by	NULL
mobility	NULL
shift	NULL
assays	NULL
revealed	NULL
that	NULL
with	NULL
the	NULL
exception	NULL
of	NULL
the	NULL
Oct2.4	NULL
isoform	NULL
,	NULL
all	NULL
isoforms	NULL
accumulated	NULL
to	NULL
comparable	NULL
levels	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
.	NULL

Western	NULL
(	NULL
im-munoblot	NULL
)	NULL
analyses	NULL
confirmed	NULL
that	NULL
the	NULL
levels	NULL
of	NULL
expression	NULL
determined	NULL
by	NULL
the	NULL
mobility	NULL
shift	NULL
assays	NULL
correlated	NULL
with	NULL
the	NULL
amount	NULL
of	NULL
stable	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
the	NULL
transfected	NULL
cells	NULL
contained	NULL
much	NULL
more	NULL
exogenous	NULL
Oct2	NULL
protein	NULL
than	NULL
endogenous	NULL
Oct2	NULL
factors	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
compare	NULL
lane	NULL
1	NULL
with	NULL
lanes	NULL
2	NULL
to	NULL
7	NULL
)	NULL
.	NULL

The	NULL
assumption	NULL
that	NULL
endogenous	NULL
and	NULL
exogenous	NULL
Oct	NULL
proteins	NULL
compete	NULL
for	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
enhancer	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
inactive	NULL
Oct	NULL
proteins	NULL
repressed	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
enhancer	NULL
constructs	NULL
to	NULL
levels	NULL
of	NULL
the	NULL
reporters	NULL
bearing	NULL
mutated	NULL
octamer	NULL
motifs	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
measured	NULL
activity	NULL
is	NULL
almost	NULL
exclusively	NULL
contributed	NULL
by	NULL
the	NULL
transfected	NULL
isoform	NULL
.	NULL

Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
Oct	NULL
?	NULL

TRANSACTIVATION	NULL
AND	NULL
B-CELL-RESTRICTED	NULL
ACTIVITY	NULL
3109	NULL
A	NULL
$	NULL
194	NULL
NIH/3T3	NULL
&	NULL
2	NULL
G	NULL
Bd	NULL
Â®	NULL
K2	NULL
L-3	NULL
2	NULL
0â	NULL
â	NULL
_	NULL
'	NULL
_	NULL
â	NULL
_	NULL
â	NULL
_	NULL
â	NULL
a	NULL
aq	NULL
%	NULL
a	NULL
a	NULL
T	NULL
a	NULL
T	NULL
Â§	NULL
a	NULL
Â§	NULL
a	NULL
ted	NULL
0	NULL
bel	NULL
0	NULL
gl	NULL
0	NULL
cel	NULL
wl	NULL
-	NULL
ml	NULL
0	NULL
40	NULL
<	NULL
]	NULL
V	NULL
Q	NULL
Q	NULL
V	NULL
Wo	NULL
Q	NULL
VQ	NULL
VQ	NULL
2A	NULL
A	NULL
A	NULL
a	NULL
2	NULL
2A	NULL
A	NULL
2	NULL
B	NULL
a	NULL
ch-lys	NULL
luciferase	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
enhancer	NULL
E4	NULL
Oct	NULL
50	NULL
bp	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Activity	NULL
of	NULL
the	NULL
various	NULL
reporter	NULL
constructs	NULL
in	NULL
$	NULL
194	NULL
and	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Plasmids	NULL
were	NULL
transfected	NULL
into	NULL
either	NULL
$	NULL
194	NULL
cells	NULL
or	NULL
NIH	NULL
3T3	NULL
cells	NULL
,	NULL
and	NULL
enzyme	NULL
activity	NULL
was	NULL
determined	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
the	NULL
enhancerless	NULL
pCL	NULL
plasmid	NULL
was	NULL
arbitrarily	NULL
set	NULL
to	NULL
10	NULL
for	NULL
each	NULL
cell	NULL
type	NULL
.	NULL

The	NULL
letters	NULL
in	NULL
parentheses	NULL
identify	NULL
the	NULL
enhancer	NULL
present	NULL
in	NULL
the	NULL
constructs	NULL
.	NULL

Abbreviations	NULL
:	NULL
ED	NULL
,	NULL
wild-type	NULL
E4	NULL
and	NULL
octamer	NULL
motifs	NULL
;	NULL
eD	NULL
,	NULL
mutant	NULL
E4	NULL
motif	NULL
,	NULL
wild-type	NULL
octamer	NULL
motif	NULL
;	NULL
Ed	NULL
,	NULL
wild-type	NULL
E4	NULL
motif	NULL
,	NULL
mutant	NULL
octamer	NULL
motif	NULL
.	NULL

Transfection	NULL
efficiencies	NULL
were	NULL
controlled	NULL
by	NULL
inclusion	NULL
of	NULL
a	NULL
B-galactosidase	NULL
expression	NULL
construct	NULL
.	NULL

Standard	NULL
deviations	NULL
are	NULL
indicated	NULL
by	NULL
error	NULL
bars	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
representation	NULL
of	NULL
the	NULL
reporter	NULL
construct	NULL
.	NULL

The	NULL
chicken	NULL
lysozyme	NULL
promoter	NULL
from	NULL
-579	NULL
to	NULL
+15	NULL
is	NULL
represented	NULL
by	NULL
the	NULL
stippled	NULL
box	NULL
;	NULL
luciferase	NULL
gene	NULL
and	NULL
the	NULL
rabbit	NULL
B-globin	NULL
splice	NULL
and	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
region	NULL
are	NULL
shown	NULL
as	NULL
empty	NULL
rectangles	NULL
.	NULL

The	NULL
black	NULL
box	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
the	NULL
multimerized	NULL
enhancer	NULL
when	NULL
present	NULL
.	NULL

The	NULL
blowup	NULL
shows	NULL
the	NULL
orientation	NULL
of	NULL
the	NULL
E4	NULL
and	NULL
octamer	NULL
motifs	NULL
in	NULL
the	NULL
constructs	NULL
.	NULL

Differential	NULL
contribution	NULL
of	NULL
the	NULL
Oct2	NULL
transactivation	NULL
domains	NULL
to	NULL
enhancer	NULL
stimulation	NULL
.	NULL

The	NULL
low	NULL
activity	NULL
of	NULL
the	NULL
Oct2.4	NULL
isoform	NULL
could	NULL
be	NULL
attributed	NULL
to	NULL
low	NULL
protein	NULL
accumulation	NULL
.	NULL

The	NULL
other	NULL
two	NULL
Oct2	NULL
isoforms	NULL
that	NULL
do	NULL
not	NULL
yield	NULL
efficient	NULL
stimulation	NULL
show	NULL
normal	NULL
stability	NULL
,	NULL
however	NULL
.	NULL

The	NULL
differences	NULL
be	NULL
tween	NULL
Oct2.3	NULL
and	NULL
Oct2.5	NULL
compared	NULL
with	NULL
the	NULL
more	NULL
active	NULL
Oct2	NULL
isoforms	NULL
are	NULL
localized	NULL
in	NULL
different	NULL
regions	NULL
of	NULL
the	NULL
Oct2	NULL
protein	NULL
.	NULL

The	NULL
Oct2.5	NULL
isoform	NULL
is	NULL
the	NULL
largest	NULL
isoform	NULL
that	NULL
carries	NULL
an	NULL
extended	NULL
C	NULL
terminus	NULL
due	NULL
to	NULL
an	NULL
out-of-frame	NULL
insertion	NULL
of	NULL
a	NULL
miniexon	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
Oct2.3	NULL
isoform	NULL
3110	NULL
ANNWEILER	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

Cer	NULL
.	NULL

B1or	NULL
.	NULL

A	NULL
600	NULL
2000	NULL
>	NULL
,	NULL
500	NULL
_	NULL
-	NULL
b=	NULL
>	NULL
.	NULL

i	NULL
ome	NULL
bst	NULL
>	NULL
C	NULL
z	NULL
C	NULL
C	NULL
2	NULL
1000	NULL
C3	NULL
400	NULL
M	NULL
E	NULL
>	NULL
2	NULL
<	NULL
2	NULL
Bs	NULL
&	NULL
-	NULL
300	NULL
I	NULL
faa	NULL
1	NULL
2	NULL
:	NULL
3	NULL
4	NULL
5	NULL
6	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
pCL	NULL
(	NULL
eD	NULL
)	NULL
pCL	NULL
(	NULL
Ed	NULL
)	NULL
200	NULL
100	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
910	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
21	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
pCL	NULL
(	NULL
eD	NULL
)	NULL
pCL	NULL
(	NULL
Ed	NULL
)	NULL
B	NULL
C	NULL
8	NULL
Oct2.1	NULL
Oct2.3	NULL
Oct2.4	NULL
49	NULL
Oct2.6	NULL
TA-1	NULL
POU	NULL
domain	NULL
TA-2	NULL
OctI	NULL
Oct2	NULL
Oct	NULL
2.3	NULL
Oct	NULL
2.4	NULL
Oct	NULL
2.5	NULL
Oct	NULL
2.6	NULL
Oct2-VP16	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Cotransfection	NULL
of	NULL
Oct2	NULL
isoforms	NULL
can	NULL
stimulate	NULL
the	NULL
octamer-containing	NULL
enhancer	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Three	NULL
micrograms	NULL
of	NULL
the	NULL
respective	NULL
reporter	NULL
constructs	NULL
was	NULL
cotransfected	NULL
with	NULL
2	NULL
pg	NULL
of	NULL
expression	NULL
vectors	NULL
carrying	NULL
the	NULL
different	NULL
Oct2	NULL
isoforms	NULL
into	NULL
$	NULL
194	NULL
cells	NULL
.	NULL

All	NULL
expression	NULL
values	NULL
are	NULL
expressed	NULL
in	NULL
relation	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
construct	NULL
cotransfected	NULL
with	NULL
the	NULL
parental	NULL
expression	NULL
vector	NULL
(	NULL
bar	NULL
1	NULL
)	NULL
.	NULL

This	NULL
value	NULL
was	NULL
set	NULL
to	NULL
100	NULL
.	NULL

Bars	NULL
:	NULL
1	NULL
to	NULL
7	NULL
,	NULL
cotransfections	NULL
with	NULL
the	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
reporter	NULL
plasmid	NULL
;	NULL
8	NULL
to	NULL
14	NULL
,	NULL
cotransfection	NULL
with	NULL
the	NULL
pCL	NULL
(	NULL
eD	NULL
)	NULL
reporter	NULL
plasmid	NULL
;	NULL
15	NULL
to	NULL
21	NULL
,	NULL
cotransfection	NULL
with	NULL
the	NULL
pCL	NULL
(	NULL
Ed	NULL
)	NULL
reporter	NULL
plasmid	NULL
.	NULL

The	NULL
parental	NULL
expression	NULL
vector	NULL
(	NULL
bars	NULL
1	NULL
,	NULL
8	NULL
,	NULL
and	NULL
15	NULL
)	NULL
,	NULL
a	NULL
vector	NULL
expressing	NULL
the	NULL
Oct2.1	NULL
isoform	NULL
(	NULL
bars	NULL
2	NULL
,	NULL
9	NULL
,	NULL
and	NULL
16	NULL
)	NULL
,	NULL
the	NULL
Oct2.2	NULL
isoform	NULL
(	NULL
bars	NULL
3	NULL
,	NULL
10	NULL
,	NULL
and	NULL
17	NULL
)	NULL
,	NULL
the	NULL
Oct2.3	NULL
isoform	NULL
(	NULL
bars	NULL
4	NULL
,	NULL
11	NULL
,	NULL
and	NULL
18	NULL
)	NULL
,	NULL
the	NULL
Oct2.4	NULL
isoform	NULL
(	NULL
bars	NULL
5	NULL
,	NULL
12	NULL
,	NULL
and	NULL
19	NULL
)	NULL
,	NULL
the	NULL
Oct2.5	NULL
isoform	NULL
(	NULL
bars	NULL
6	NULL
,	NULL
13	NULL
,	NULL
and	NULL
20	NULL
)	NULL
,	NULL
or	NULL
the	NULL
Oct2.6	NULL
isoform	NULL
(	NULL
bars	NULL
7	NULL
,	NULL
14	NULL
,	NULL
and	NULL
21	NULL
)	NULL
was	NULL
included	NULL
in	NULL
the	NULL
cotransfections	NULL
.	NULL

The	NULL
insert	NULL
shows	NULL
the	NULL
stimulation	NULL
of	NULL
the	NULL
different	NULL
reporter	NULL
constructs	NULL
by	NULL
the	NULL
Oct2-VP16	NULL
fusion	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
.	NULL

Bars	NULL
:	NULL
1	NULL
,	NULL
3	NULL
,	NULL
and	NULL
5	NULL
,	NULL
cotransfection	NULL
with	NULL
the	NULL
parental	NULL
expression	NULL
vector	NULL
;	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
,	NULL
cotransfection	NULL
with	NULL
the	NULL
Oct2-VP16	NULL
fusion	NULL
.	NULL

Standard	NULL
deviations	NULL
are	NULL
indicated	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
contains	NULL
a	NULL
short	NULL
insert	NULL
of	NULL
22	NULL
amino	NULL
acids	NULL
in	NULL
front	NULL
of	NULL
the	NULL
glutamine-rich	NULL
transactivation	NULL
domain	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
;	NULL
for	NULL
details	NULL
,	NULL
see	NULL
reference	NULL
43	NULL
)	NULL
.	NULL

From	NULL
these	NULL
considerations	NULL
,	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
two	NULL
described	NULL
transactivation	NULL
domains	NULL
of	NULL
the	NULL
Oct2	NULL
protein	NULL
to	NULL
enhancer	NULL
transactivation	NULL
remained	NULL
unclear	NULL
.	NULL

To	NULL
directly	NULL
address	NULL
the	NULL
question	NULL
of	NULL
whether	NULL
both	NULL
transactivation	NULL
domains	NULL
are	NULL
equally	NULL
important	NULL
for	NULL
enhancer	NULL
stimulation	NULL
,	NULL
we	NULL
cotransfected	NULL
the	NULL
reporter	NULL
plasmids	NULL
with	NULL
Oct2	NULL
mutants	NULL
lacking	NULL
the	NULL
whole	NULL
region	NULL
either	NULL
N	NULL
terminal	NULL
or	NULL
C	NULL
terminal	NULL
of	NULL
the	NULL
POU	NULL
domain	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

The	NULL
parental	NULL
Oct2	NULL
isoform	NULL
was	NULL
the	NULL
human	NULL
homolog	NULL
of	NULL
the	NULL
mouse	NULL
Oct2.2	NULL
form	NULL
.	NULL

Expression	NULL
of	NULL
these	NULL
mutants	NULL
in	NULL
HeLa	NULL
cells	NULL
efficiently	NULL
stimulated	NULL
an	NULL
octamer-containing	NULL
promoter	NULL
.	NULL

The	NULL
N-terminal	NULL
deletion	NULL
had	NULL
shown	NULL
a	NULL
moderately	NULL
reduced	NULL
transactivating	NULL
potential	NULL
(	NULL
25	NULL
)	NULL
.	NULL

These	NULL
deletion	NULL
mutants	NULL
had	NULL
previously	NULL
been	NULL
characterized	NULL
in	NULL
non-B	NULL
cells	NULL
only	NULL
,	NULL
and	NULL
we	NULL
therefore	NULL
determined	NULL
whether	NULL
they	NULL
showed	NULL
similar	NULL
promoter	NULL
transactivation	NULL
features	NULL
in	NULL
the	NULL
B-cell	NULL
line	NULL
.	NULL

We	NULL
cotransfected	NULL
them	NULL
together	NULL
with	NULL
a	NULL
luciferase	NULL
reporter	NULL
carrying	NULL
a	NULL
single	NULL
wild-type	NULL
or	NULL
mutant	NULL
octamer	NULL
motif	NULL
upstream	NULL
of	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
TATA	NULL
box	NULL
into	NULL
the	NULL
$	NULL
194	NULL
cell	NULL
line	NULL
.	NULL

As	NULL
it	NULL
had	NULL
been	NULL
shown	NULL
that	NULL
overexpression	NULL
of	NULL
Octl	NULL
is	NULL
also	NULL
capable	NULL
of	NULL
activating	NULL
an	NULL
octamer-containing	NULL
promoter	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
,	NULL
we	NULL
included	NULL
Octl	NULL
in	NULL
our	NULL
analyses	NULL
,	NULL
too	NULL
.	NULL

The	NULL
results	NULL
closely	NULL
resembled	NULL
those	NULL
of	NULL
the	NULL
HeLa	NULL
cotransfection	NULL
experiment	NULL
.	NULL

Deletion	NULL
of	NULL
either	NULL
transactivation	NULL
domain	NULL
did	NULL
not	NULL
significantly	NULL
affect	NULL
the	NULL
stimulatory	NULL
potential	NULL
,	NULL
confirming	NULL
the	NULL
previous	NULL
notion	NULL
of	NULL
a	NULL
functional	NULL
redundancy	NULL
of	NULL
the	NULL
two	NULL
transactivation	NULL
domains	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
results	NULL
with	NULL
HeLa	NULL
cells	NULL
,	NULL
Octl	NULL
also	NULL
weakly	NULL
stimulated	NULL
the	NULL
octamer-containing	NULL
promoter	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
a	NULL
strikingly	NULL
different	NULL
picture	NULL
emerged	NULL
when	NULL
these	NULL
expression	NULL
vectors	NULL
were	NULL
cotransfected	NULL
with	NULL
the	NULL
reporter	NULL
constructs	NULL
bearing	NULL
the	NULL
multimerized	NULL
octamer	NULL
enhancer	NULL
element	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

Whereas	NULL
removal	NULL
of	NULL
the	NULL
glutamine-rich	NULL
N-terminal	NULL
transactivation	NULL
domain	NULL
had	NULL
essentially	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
transactivating	NULL
potential	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
C-terminal	NULL
region	NULL
turned	NULL
out	NULL
to	NULL
be	NULL
a	NULL
strong	NULL
down	NULL
mutation	NULL
.	NULL

With	NULL
increasing	NULL
amounts	NULL
of	NULL
cotransfected	NULL
expression	NULL
vector	NULL
,	NULL
this	NULL
difference	NULL
became	NULL
increasingly	NULL
obvious	NULL
.	NULL

The	NULL
intact	NULL
Oct2	NULL
isoform	NULL
showed	NULL
somewhat	NULL
lower	NULL
levels	NULL
of	NULL
transactivation	NULL
at	NULL
low	NULL
concentrations	NULL
of	NULL
expression	NULL
vector	NULL
due	NULL
to	NULL
reduced	NULL
protein	NULL
accumulation	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

At	NULL
elevated	NULL
expression	NULL
vector	NULL
concentrations	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
obliterated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Most	NULL
surprisingly	NULL
,	NULL
cotransfection	NULL
of	NULL
the	NULL
Octl	NULL
expression	NULL
vector	NULL
resulted	NULL
in	NULL
repression	NULL
of	NULL
the	NULL
enhancer	NULL
construct	NULL
.	NULL

The	NULL
level	NULL
of	NULL
expression	NULL
seen	NULL
with	NULL
cotransfected	NULL
Octl	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
one	NULL
obtained	NULL
with	NULL
the	NULL
reporter	NULL
construct	NULL
bearing	NULL
the	NULL
multimerized	NULL
octamer	NULL
mutation	NULL
.	NULL

This	NULL
result	NULL
confirmed	NULL
the	NULL
above	NULL
speculations	NULL
that	NULL
endogenous	NULL
and	NULL
exogenous	NULL
Oct	NULL
proteins	NULL
compete	NULL
for	NULL
available	NULL
binding	NULL
sites	NULL
and	NULL
that	NULL
at	NULL
a	NULL
high	NULL
concentration	NULL
of	NULL
exogenous	NULL
protein	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
endogenous	NULL
proteins	NULL
becomes	NULL
negligible	NULL
.	NULL

The	NULL
repression	NULL
of	NULL
octamer-dependent	NULL
enhancer	NULL
activity	NULL
by	NULL
Octl	NULL
allowed	NULL
us	NULL
to	NULL
reassess	NULL
the	NULL
importance	NULL
of	NULL
individual	NULL
domains	NULL
of	NULL
the	NULL
Oct2	NULL
protein	NULL
by	NULL
using	NULL
Oct1l-Oct2	NULL
fusions	NULL
.	NULL

Both	NULL
proteins	NULL
are	NULL
very	NULL
similar	NULL
in	NULL
the	NULL
POU	NULL
domain	NULL
;	NULL
their	NULL
Oct	NULL
?	NULL

TRANSACTIVATION	NULL
AND	NULL
B-CELL-RESTRICTED	NULL
ACTIVITY	NULL
3111	NULL
POU-specific	NULL
domains	NULL
are	NULL
virtually	NULL
identical	NULL
(	NULL
at	NULL
74	NULL
of	NULL
75	NULL
positions	NULL
)	NULL
,	NULL
and	NULL
their	NULL
POU-homeo	NULL
domains	NULL
are	NULL
also	NULL
well	NULL
conserved	NULL
(	NULL
53	NULL
of	NULL
60	NULL
positions	NULL
)	NULL
but	NULL
nevertheless	NULL
show	NULL
some	NULL
functional	NULL
differences	NULL
with	NULL
respect	NULL
to	NULL
protein-protein	NULL
interactions	NULL
(	NULL
36	NULL
)	NULL
.	NULL

We	NULL
cotransfected	NULL
a	NULL
set	NULL
of	NULL
Octl-Oct2	NULL
fusion	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
(	NULL
40	NULL
)	NULL
with	NULL
the	NULL
enhancer	NULL
reporter	NULL
,	NULL
and	NULL
the	NULL
results	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
.	NULL

For	NULL
enhancer	NULL
transactivation	NULL
,	NULL
the	NULL
Oct2	NULL
carboxy-terminal	NULL
domain	NULL
was	NULL
absolutely	NULL
required	NULL
.	NULL

Whenever	NULL
the	NULL
Octl	NULL
C	NULL
terminus	NULL
was	NULL
present	NULL
in	NULL
the	NULL
fusion	NULL
proteins	NULL
,	NULL
the	NULL
expression	NULL
level	NULL
was	NULL
repressed	NULL
.	NULL

Neither	NULL
the	NULL
Oct2	NULL
N-terminal	NULL
transactivation	NULL
domain	NULL
nor	NULL
the	NULL
POU	NULL
domain	NULL
of	NULL
Oct2	NULL
had	NULL
a	NULL
measurable	NULL
stimulatory	NULL
effect	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Oct1	NULL
C	NULL
terminus	NULL
.	NULL

In	NULL
all	NULL
our	NULL
transfections	NULL
,	NULL
the	NULL
hybrid	NULL
construct	NULL
2-1-2	NULL
was	NULL
somewhat	NULL
more	NULL
active	NULL
than	NULL
the	NULL
1-1-2	NULL
hybrid	NULL
.	NULL

We	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
that	NULL
this	NULL
difference	NULL
is	NULL
due	NULL
to	NULL
slight	NULL
differences	NULL
in	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
respective	NULL
proteins	NULL
.	NULL

The	NULL
transactivation	NULL
by	NULL
the	NULL
wild-type	NULL
Oct2	NULL
protein	NULL
was	NULL
always	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
the	NULL
fusion	NULL
protein	NULL
,	NULL
in	NULL
which	NULL
only	NULL
the	NULL
Oct2	NULL
POU	NULL
domain	NULL
was	NULL
replaced	NULL
by	NULL
the	NULL
respective	NULL
domain	NULL
from	NULL
Octl	NULL
.	NULL

This	NULL
difference	NULL
remained	NULL
even	NULL
when	NULL
increasing	NULL
concentrations	NULL
of	NULL
the	NULL
fusion	NULL
protein	NULL
expression	NULL
vectors	NULL
were	NULL
used	NULL
and	NULL
was	NULL
not	NULL
due	NULL
to	NULL
different	NULL
expression	NULL
levels	NULL
of	NULL
the	NULL
respective	NULL
proteins	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
map	NULL
the	NULL
region	NULL
within	NULL
the	NULL
Oct2	NULL
C	NULL
terminus	NULL
required	NULL
for	NULL
remote	NULL
activation	NULL
more	NULL
precisely	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
Oct2	NULL
C	NULL
terminus	NULL
to	NULL
promoter	NULL
activation	NULL
in	NULL
HeLa	NULL
cells	NULL
had	NULL
revealed	NULL
that	NULL
the	NULL
C-terminal	NULL
18	NULL
amino	NULL
acids	NULL
were	NULL
important	NULL
for	NULL
transactivation	NULL
(	NULL
9	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
Oct2	NULL
C-terminal	NULL
domain	NULL
contains	NULL
a	NULL
putative	NULL
leucine	NULL
zipper	NULL
motif	NULL
(	NULL
1a	NULL
,	NULL
24	NULL
,	NULL
31	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
this	NULL
motif	NULL
did	NULL
not	NULL
affect	NULL
promoter	NULL
transactivation	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
9	NULL
,	NULL
40	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
several	NULL
C-terminal	NULL
mutations	NULL
for	NULL
the	NULL
capacity	NULL
to	NULL
activate	NULL
from	NULL
a	NULL
distance	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
previous	NULL
observation	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
,	NULL
the	NULL
deletion	NULL
of	NULL
most	NULL
of	NULL
the	NULL
C	NULL
terminus	NULL
(	NULL
A377	NULL
to	NULL
463	NULL
)	NULL
reduced	NULL
activity	NULL
2.5-fold	NULL
and	NULL
therefore	NULL
essentially	NULL
abolished	NULL
enhancer	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
deletion	NULL
of	NULL
almost	NULL
the	NULL
complete	NULL
leucine	NULL
zipper	NULL
motif	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
observed	NULL
transactivation	NULL
.	NULL

The	NULL
region	NULL
C	NULL
terminal	NULL
to	NULL
the	NULL
leucine	NULL
zipper	NULL
was	NULL
necessary	NULL
for	NULL
full	NULL
enhance-ing	NULL
activity	NULL
,	NULL
however	NULL
.	NULL

Both	NULL
an	NULL
internal	NULL
deletion	NULL
(	NULL
A377	NULL
to	NULL
443	NULL
)	NULL
and	NULL
the	NULL
removal	NULL
of	NULL
the	NULL
18	NULL
C-terminal	NULL
amino	NULL
acids	NULL
(	NULL
A443	NULL
to	NULL
463	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
partial	NULL
reduction	NULL
of	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
stabilities	NULL
of	NULL
the	NULL
various	NULL
proteins	NULL
with	NULL
deletions	NULL
were	NULL
observed	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Oct2-mediated	NULL
enhancer	NULL
activation	NULL
is	NULL
B	NULL
cell	NULL
specific	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
Oct2	NULL
transcription	NULL
factor	NULL
can	NULL
efficiently	NULL
stimulate	NULL
from	NULL
a	NULL
promoter	NULL
position	NULL
and	NULL
also	NULL
from	NULL
a	NULL
distant	NULL
enhancer	NULL
position	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
ubiquitous	NULL
Octl	NULL
transcription	NULL
factor	NULL
can	NULL
stimulate	NULL
only	NULL
from	NULL
a	NULL
proximal	NULL
promoter	NULL
position	NULL
.	NULL

Whereas	NULL
promoter	NULL
transactivation	NULL
can	NULL
be	NULL
achieved	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
(	NULL
9	NULL
,	NULL
24	NULL
,	NULL
25	NULL
,	NULL
40	NULL
)	NULL
,	NULL
activity	NULL
from	NULL
a	NULL
remote	NULL
position	NULL
requires	NULL
an	NULL
activity	NULL
that	NULL
is	NULL
present	NULL
in	NULL
B	NULL
cells	NULL
but	NULL
absent	NULL
from	NULL
several	NULL
non-B-cell	NULL
lines	NULL
.	NULL

There	NULL
are	NULL
several	NULL
possible	NULL
explanations	NULL
for	NULL
this	NULL
observa-tion	NULL
.	NULL

We	NULL
favor	NULL
the	NULL
idea	NULL
that	NULL
Oct2	NULL
needs	NULL
to	NULL
interact	NULL
with	NULL
a	NULL
by	NULL
error	NULL
bars	NULL
.	NULL

Abbreviations	NULL
,	NULL
same	NULL
as	NULL
for	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
outline	NULL
of	NULL
the	NULL
various	NULL
Oct2	NULL
isoforms	NULL
and	NULL
the	NULL
Oct2-VP16	NULL
fusion	NULL
.	NULL

Oct2	NULL
transactivation	NULL
domains	NULL
TA-1	NULL
and	NULL
TA-2	NULL
are	NULL
indicated	NULL
.	NULL

For	NULL
details	NULL
on	NULL
the	NULL
Oct2	NULL
isoforms	NULL
,	NULL
see	NULL
reference	NULL
43	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Aliquots	NULL
of	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
a	NULL
labeled	NULL
octamer-containing	NULL
probe	NULL
.	NULL

$	NULL
194	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
parental	NULL
expression	NULL
vector	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
expression	NULL
vectors	NULL
containing	NULL
the	NULL
cDNAs	NULL
coding	NULL
for	NULL
Oct2.1	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
Oct2.2	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
Oct2.3	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
Oct2.4	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
Oct2.5	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
or	NULL
Oct2.6	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

3112	NULL
ANNWEILER	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
400W	NULL
I	NULL
>	NULL
.	NULL

S	NULL
300	NULL
{	NULL
3	NULL
's	NULL
~	NULL
o	NULL
see	NULL
3	NULL
-	NULL
200	NULL
C	NULL
100	NULL
0	NULL
B	NULL
NH2	NULL
POT	NULL
Coon	NULL
Oct2	NULL
os	NULL
s	NULL
I	NULL
T	NULL
]	NULL
Oct2A	NULL
(	NULL
Oct2AN	NULL
Oct1	NULL
(	NULL
a	NULL
aran	NULL
1	NULL
H	NULL
fv	NULL
]	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

The	NULL
Oct2	NULL
C	NULL
terminus	NULL
is	NULL
required	NULL
for	NULL
efficient	NULL
enhancer	NULL
stimulation	NULL
.	NULL

Reporter	NULL
constructs	NULL
were	NULL
cotransfected	NULL
either	NULL
with	NULL
an	NULL
Oct1	NULL
expression	NULL
vector	NULL
(	NULL
18	NULL
)	NULL
or	NULL
with	NULL
the	NULL
outlined	NULL
Oct2	NULL
deletions	NULL
(	NULL
B	NULL
)	NULL
into	NULL
$	NULL
194	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
value	NULL
of	NULL
the	NULL
reporter	NULL
containing	NULL
a	NULL
wild-type	NULL
octamer	NULL
motif	NULL
(	NULL
s	NULL
)	NULL
is	NULL
set	NULL
to	NULL
100	NULL
.	NULL

Standard	NULL
deviations	NULL
are	NULL
indicated	NULL
by	NULL
error	NULL
bars	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cotransfections	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
expression	NULL
vectors	NULL
.	NULL

The	NULL
respective	NULL
expression	NULL
vectors	NULL
(	NULL
0.2	NULL
pg	NULL
[	NULL
bars	NULL
3	NULL
,	NULL
4	NULL
,	NULL
9	NULL
,	NULL
10	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
21	NULL
,	NULL
and	NULL
22	NULL
]	NULL
,	NULL
0.5	NULL
ug	NULL
[	NULL
bars	NULL
5	NULL
,	NULL
6	NULL
,	NULL
11	NULL
,	NULL
12	NULL
,	NULL
17	NULL
,	NULL
18	NULL
,	NULL
23	NULL
,	NULL
and	NULL
24	NULL
}	NULL
,	NULL
or	NULL
1.5	NULL
ug	NULL
[	NULL
bars	NULL
7	NULL
,	NULL
8	NULL
,	NULL
13	NULL
,	NULL
14	NULL
,	NULL
19	NULL
,	NULL
20	NULL
,	NULL
25	NULL
,	NULL
and	NULL
26	NULL
]	NULL
)	NULL
were	NULL
cotransfected	NULL
with	NULL
3.5	NULL
ug	NULL
of	NULL
either	NULL
the	NULL
wild-type	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
reporter	NULL
plasmid	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
or	NULL
the	NULL
mutant	NULL
pCL	NULL
(	NULL
Ed	NULL
)	NULL
reporter	NULL
plasmid	NULL
(	NULL
hatched	NULL
bars	NULL
)	NULL
.	NULL

In	NULL
all	NULL
transfections	NULL
,	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
expression	NULL
plasmid	NULL
was	NULL
adjusted	NULL
to	NULL
1.5	NULL
ug	NULL
with	NULL
the	NULL
parental	NULL
expression	NULL
vector	NULL
.	NULL

Bars	NULL
1	NULL
and	NULL
2	NULL
,	NULL
parental	NULL
expression	NULL
vector	NULL
only	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
outline	NULL
of	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
Oct2	NULL
deletion	NULL
constructs	NULL
.	NULL

The	NULL
parental	NULL
Oct2	NULL
represents	NULL
the	NULL
human	NULL
Oct2.2	NULL
homolog	NULL
.	NULL

Oct2AC	NULL
contains	NULL
amino	NULL
acids	NULL
2	NULL
to	NULL
370	NULL
;	NULL
Oct2AN	NULL
contains	NULL
amino	NULL
acids	NULL
194	NULL
to	NULL
479	NULL
(	NULL
see	NULL
reference	NULL
25	NULL
for	NULL
details	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Aliquots	NULL
of	NULL
a	NULL
representative	NULL
set	NULL
of	NULL
transfected	NULL
cells	NULL
from	NULL
the	NULL
enhancer	NULL
cotransfections	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
the	NULL
octamer-containing	NULL
probe	NULL
.	NULL

B-cell-specific	NULL
cofactor	NULL
in	NULL
order	NULL
to	NULL
exert	NULL
its	NULL
function	NULL
from	NULL
a	NULL
distance	NULL
.	NULL

Studies	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
promoter	NULL
function	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
led	NULL
to	NULL
the	NULL
concept	NULL
of	NULL
coactivators	NULL
or	NULL
adaptors	NULL
that	NULL
communicate	NULL
the	NULL
stimulatory	NULL
signal	NULL
of	NULL
transcription	NULL
factors	NULL
to	NULL
the	NULL
basal	NULL
transcription	NULL
complex	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
22	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
involvement	NULL
of	NULL
a	NULL
so-called	NULL
bridging	NULL
factor	NULL
for	NULL
transcriptional	NULL
activation	NULL
from	NULL
a	NULL
distance	NULL
has	NULL
recently	NULL
been	NULL
described	NULL
for	NULL
the	NULL
Oct4	NULL
transcription	NULL
factor	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
balanced	NULL
coexpression	NULL
of	NULL
the	NULL
adenovirus	NULL
ElA	NULL
13S	NULL
gene	NULL
product	NULL
allowed	NULL
the	NULL
Oct4	NULL
transcription	NULL
factor	NULL
to	NULL
stimulate	NULL
a	NULL
construct	NULL
bearing	NULL
a	NULL
multimerized	NULL
octamer-containing	NULL
enhancer	NULL
.	NULL

This	NULL
multimerized	NULL
enhancer	NULL
was	NULL
essentially	NULL
identical	NULL
to	NULL
the	NULL
enhancer	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

However	NULL
,	NULL
we	NULL
do	NULL
not	NULL
think	NULL
that	NULL
an	NULL
E1AÂ¥-like	NULL
activity	NULL
is	NULL
responsible	NULL
for	NULL
B-cell-specific	NULL
Oct2	NULL
enhancer	NULL
transactiva-	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bio	NULL
.	NULL

-o	NULL
m	NULL
t	NULL
in	NULL
o	NULL
na	NULL
<	NULL
o	NULL
o	NULL
a	NULL
Oct2AN	NULL
Oct2-AC	NULL
Oct2-AN	NULL
C	NULL
Oct1	NULL
Oct2	NULL
onc	NULL
in	NULL
in	NULL
e	NULL
in	NULL
-	NULL
in	NULL
s	NULL
in	NULL
-	NULL
in	NULL
n	NULL
in	NULL
-	NULL
in	NULL
i	NULL
Octl	NULL
Oct2	NULL
Oct2-A	NULL
(	NULL
Oct2-AN	NULL
tion	NULL
.	NULL

There	NULL
is	NULL
no	NULL
evidence	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
ElA-like	NULL
activity	NULL
in	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
ectopic	NULL
expression	NULL
of	NULL
ElA	NULL
in	NULL
B	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
repress	NULL
immunoglobulin	NULL
enhancer	NULL
activity	NULL
(	NULL
13	NULL
)	NULL
.	NULL

We	NULL
have	NULL
done	NULL
experiments	NULL
in	NULL
which	NULL
ElA	NULL
was	NULL
cotransfected	NULL
into	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
our	NULL
preliminary	NULL
results	NULL
have	NULL
shown	NULL
a	NULL
repression	NULL
of	NULL
our	NULL
reporter	NULL
constructs	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

An	NULL
independent	NULL
indication	NULL
for	NULL
the	NULL
requirement	NULL
of	NULL
a	NULL
B-cell-specific	NULL
cofactor	NULL
for	NULL
enhancer	NULL
function	NULL
came	NULL
from	NULL
the	NULL
recent	NULL
analysis	NULL
of	NULL
enhancer	NULL
transactivation	NULL
by	NULL
the	NULL
bovine	NULL
papillomavirus	NULL
E2	NULL
transactivator	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
(	NULL
8	NULL
)	NULL
.	NULL

It	NULL
was	NULL
shown	NULL
that	NULL
the	NULL
E2	NULL
transactivator	NULL
could	NULL
stimulate	NULL
several	NULL
different	NULL
minimal	NULL
promoter	NULL
elements	NULL
in	NULL
a	NULL
B-cell	NULL
line	NULL
,	NULL
whereas	NULL
in	NULL
other	NULL
cell	NULL
lines	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
promoters	NULL
could	NULL
be	NULL
stimulated	NULL
.	NULL

As	NULL
there	NULL
is	NULL
no	NULL
obvious	NULL
homology	NULL
between	NULL
Oct2	NULL
and	NULL
the	NULL
E2	NULL
protein	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
hypothetical	NULL
cofactors	NULL
might	NULL
be	NULL
identical	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
the	NULL
experiments	NULL
of	NULL
Forsberg	NULL
and	NULL
Westin	NULL
(	NULL
8	NULL
)	NULL
,	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
minimal	NULL
promoter	NULL
determined	NULL
whether	NULL
the	NULL
E2	NULL
enhancer	NULL
was	NULL
active	NULL
.	NULL

Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
Oct	NULL
?	NULL

TRANSACTIVATION	NULL
AND	NULL
B-CELL-RESTRICTED	NULL
ACTIVITY	NULL
3113	NULL
A	NULL
300	NULL
E	NULL
E	NULL
G	NULL
200	NULL
Â®	NULL
B	NULL
)	NULL
e	NULL
2	NULL
100	NULL
0	NULL
*	NULL
ea	NULL
woul	NULL
wi	NULL
wat	NULL
ea	NULL
wat	NULL
ea	NULL
ca	NULL
mo-	NULL
o-	NULL
~	NULL
ct	NULL
0	NULL
Â«	NULL
=	NULL
(	NULL
0	NULL
c	NULL
0	NULL
es	NULL
a-	NULL
Â«	NULL
--	NULL
ad-	NULL
d-	NULL
Â«	NULL
<	NULL
--	NULL
_-_	NULL
a	NULL
B	NULL
NH2	NULL
POU	NULL
COOH	NULL
Oct2	NULL
(	NULL
2-2-2	NULL
)	NULL
{	NULL
I	NULL
I	NULL
]	NULL
Oct	NULL
]	NULL
(	NULL
1-1-1	NULL
)	NULL
-	NULL
Rr	NULL
rr	NULL
rr	NULL
rrr	NULL
rr	NULL
rr	NULL
rar	NULL
rr	NULL
rr	NULL
rrr	NULL
rrr	NULL
r	NULL
rrr	NULL
2-1-1	NULL
m	NULL
ZZZ	NULL
OTL	NULL
2-241	NULL
|I	NULL
I	NULL
LOO	NULL
1.1.2	NULL
GALLON	NULL
___|	NULL
1.21	NULL
G	NULL
___	NULL
VZ	NULL
rere	NULL
2-1.2	NULL
o	NULL
Â»	NULL
Â»	NULL
-	NULL
n	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Oct2	NULL
domains	NULL
contribute	NULL
differentially	NULL
to	NULL
full	NULL
enhancer	NULL
stimulation	NULL
in	NULL
$	NULL
194	NULL
B	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
indicated	NULL
Octl-Oct2	NULL
fusion	NULL
protein	NULL
expression	NULL
vectors	NULL
or	NULL
the	NULL
parental	NULL
expression	NULL
vector	NULL
(	NULL
0.5	NULL
ug	NULL
)	NULL
was	NULL
cotransfected	NULL
with	NULL
3.5	NULL
ug	NULL
of	NULL
the	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
or	NULL
the	NULL
mutant	NULL
pCL	NULL
(	NULL
Ed	NULL
)	NULL
(	NULL
hatched	NULL
bars	NULL
)	NULL
reporter	NULL
.	NULL

Standard	NULL
deviations	NULL
are	NULL
indicated	NULL
by	NULL
error	NULL
bars	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Schematic	NULL
outline	NULL
of	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
(	NULL
for	NULL
details	NULL
,	NULL
see	NULL
reference	NULL
40	NULL
)	NULL
.	NULL

The	NULL
E2	NULL
transactivator	NULL
contains	NULL
a	NULL
predicted	NULL
acidic	NULL
amphi-pathic	NULL
Â«	NULL
-helix	NULL
in	NULL
its	NULL
transactivation	NULL
domain	NULL
(	NULL
11	NULL
)	NULL
.	NULL

As	NULL
a	NULL
fusion	NULL
protein	NULL
of	NULL
Oct2	NULL
with	NULL
the	NULL
acidic	NULL
transactivation	NULL
domain	NULL
of	NULL
VP16	NULL
could	NULL
transactivate	NULL
our	NULL
reporter	NULL
construct	NULL
in	NULL
non-B	NULL
cells	NULL
,	NULL
we	NULL
think	NULL
that	NULL
distinct	NULL
mechanisms	NULL
are	NULL
responsible	NULL
for	NULL
these	NULL
two	NULL
observations	NULL
.	NULL

Alternate	NULL
models	NULL
for	NULL
the	NULL
observed	NULL
cell	NULL
type	NULL
specificity	NULL
of	NULL
Oct2	NULL
enhancer	NULL
activation	NULL
could	NULL
also	NULL
be	NULL
envisaged	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
non-B	NULL
cells	NULL
repress	NULL
this	NULL
long-distance	NULL
activity	NULL
of	NULL
Oct2	NULL
.	NULL

Support	NULL
for	NULL
such	NULL
a	NULL
model	NULL
comes	NULL
from	NULL
studies	NULL
of	NULL
immunoglobulin	NULL
extinction	NULL
in	NULL
somatic	NULL
cell	NULL
hybrids	NULL
.	NULL

In	NULL
hybrids	NULL
of	NULL
B	NULL
cells	NULL
with	NULL
fibroblasts	NULL
,	NULL
extinction	NULL
correlates	NULL
with	NULL
a	NULL
shutoff	NULL
of	NULL
Oct2	NULL
expression	NULL
(	NULL
17	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
at	NULL
least	NULL
some	NULL
hybrids	NULL
between	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
that	NULL
also	NULL
show	NULL
immunoglobulin	NULL
extinction	NULL
,	NULL
Oct2	NULL
expression	NULL
is	NULL
not	NULL
affected	NULL
(	NULL
46	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
argues	NULL
for	NULL
a	NULL
more	NULL
general	NULL
repression	NULL
mechanism	NULL
of	NULL
B-cell-specific	NULL
enhancer	NULL
function	NULL
in	NULL
non-B	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
our	NULL
results	NULL
could	NULL
also	NULL
be	NULL
explained	NULL
by	NULL
a	NULL
B-cell-specific	NULL
modification	NULL
of	NULL
either	NULL
Oct2	NULL
or	NULL
another	NULL
factor	NULL
involved	NULL
in	NULL
the	NULL
transcription	NULL
complex	NULL
.	NULL

Differential	NULL
modification	NULL
of	NULL
transcription	NULL
factors	NULL
is	NULL
clearly	NULL
correlated	NULL
with	NULL
their	NULL
respective	NULL
transactivation	NULL
properties	NULL
as	NULL
exemplified	NULL
by	NULL
the	NULL
heat	NULL
shock	NULL
transcription	NULL
factors	NULL
and	NULL
the	NULL
cyclic	NULL
AMP-induced	NULL
CREB	NULL
transcription	NULL
factor	NULL
(	NULL
33	NULL
,	NULL
45	NULL
)	NULL
.	NULL

These	NULL
differential	NULL
modifications	NULL
are	NULL
regulated	NULL
by	NULL
external	NULL
stimuli	NULL
,	NULL
however	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
,	NULL
no	NULL
example	NULL
of	NULL
a	NULL
constitutive	NULL
cell-type-dependent	NULL
difference	NULL
of	NULL
transcription	NULL
factor	NULL
modification	NULL
has	NULL
been	NULL
de-scribed	NULL
.	NULL

The	NULL
enhancer	NULL
element	NULL
used	NULL
in	NULL
our	NULL
studies	NULL
was	NULL
a	NULL
multimerized	NULL
short	NULL
fragment	NULL
from	NULL
the	NULL
heavy-chain	NULL
enhancer	NULL
3114	NULL
ANNWEILER	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

Cec	NULL
.	NULL

BioL	NULL
.	NULL

POU-domain	NULL
LZip	NULL
Â£3522	NULL
?	NULL

â	NULL
1-463	NULL
o	NULL
|	NULL
100	NULL
A377-399	NULL
|	NULL
]	NULL
40	NULL
(	NULL
+/-	NULL
2	NULL
)	NULL
A377-399	NULL
C	NULL
1	NULL
-C	NULL
G	NULL
-	NULL
102	NULL
(	NULL
+/-9	NULL
)	NULL
A446-463	NULL
[	NULL
a	NULL
]	NULL
55	NULL
(	NULL
+/-	NULL
2	NULL
)	NULL
A377-443	NULL
C	NULL
;	NULL
]	NULL
5	NULL
-	NULL
6	NULL
(	NULL
@	NULL
/1	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

The	NULL
leucine	NULL
zipper	NULL
(	NULL
LZip	NULL
)	NULL
motif	NULL
is	NULL
dispensable	NULL
for	NULL
enhancer	NULL
activation	NULL
.	NULL

$	NULL
194	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
3	NULL
ug	NULL
of	NULL
the	NULL
pCL	NULL
(	NULL
ED	NULL
)	NULL
reporter	NULL
construct	NULL
and	NULL
2	NULL
ug	NULL
of	NULL
the	NULL
Oct2	NULL
expression	NULL
vectors	NULL
bearing	NULL
the	NULL
indicated	NULL
deletions	NULL
(	NULL
9	NULL
)	NULL
.	NULL

The	NULL
parental	NULL
Oct2	NULL
isoform	NULL
was	NULL
the	NULL
human	NULL
Oct2.1	NULL
homolog	NULL
.	NULL

The	NULL
POU	NULL
domain	NULL
and	NULL
the	NULL
putative	NULL
leucine	NULL
zipper	NULL
motif	NULL
are	NULL
indicated	NULL
as	NULL
stippled	NULL
boxes	NULL
.	NULL

The	NULL
activities	NULL
of	NULL
the	NULL
various	NULL
deletion	NULL
constructs	NULL
are	NULL
expressed	NULL
in	NULL
relation	NULL
to	NULL
the	NULL
full-length	NULL
Oct2	NULL
protein	NULL
.	NULL

Standard	NULL
deviations	NULL
from	NULL
three	NULL
independent	NULL
transfection	NULL
experiments	NULL
are	NULL
given	NULL
in	NULL
parentheses	NULL
.	NULL

containing	NULL
the	NULL
octamer	NULL
motif	NULL
.	NULL

This	NULL
artificial	NULL
enhancer	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
to	NULL
behave	NULL
as	NULL
a	NULL
bona	NULL
fide	NULL
B-cell-specific	NULL
enhancer	NULL
element	NULL
(	NULL
10	NULL
)	NULL
.	NULL

We	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
Oct2	NULL
might	NULL
behave	NULL
differently	NULL
when	NULL
assayed	NULL
on	NULL
the	NULL
single	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
natural	NULL
enhancer	NULL
rather	NULL
than	NULL
on	NULL
the	NULL
multimerized	NULL
synthetic	NULL
enhancer	NULL
element	NULL
.	NULL

Neverthe-less	NULL
,	NULL
the	NULL
Oct2	NULL
enhancer	NULL
transactivation	NULL
potential	NULL
can	NULL
not	NULL
be	NULL
studied	NULL
with	NULL
the	NULL
complete	NULL
heavy-chain	NULL
enhancer	NULL
element	NULL
in	NULL
which	NULL
the	NULL
octamer	NULL
motif	NULL
contributes	NULL
only	NULL
part	NULL
of	NULL
the	NULL
overall	NULL
activity	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
Oct2	NULL
C	NULL
terminus	NULL
is	NULL
required	NULL
for	NULL
efficient	NULL
enhancer	NULL
stimulation	NULL
.	NULL

Whereas	NULL
the	NULL
two	NULL
transactivation	NULL
domains	NULL
of	NULL
Oct2	NULL
are	NULL
functionally	NULL
redundant	NULL
with	NULL
respect	NULL
to	NULL
activation	NULL
of	NULL
an	NULL
octamer-containing	NULL
promoter	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
non-B	NULL
cells	NULL
,	NULL
Oct2	NULL
function	NULL
from	NULL
a	NULL
distance	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
C	NULL
terminus	NULL
.	NULL

It	NULL
is	NULL
at	NULL
present	NULL
unclear	NULL
whether	NULL
the	NULL
target	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
Oct2	NULL
C	NULL
terminus	NULL
is	NULL
identical	NULL
for	NULL
promoter	NULL
and	NULL
enhancer	NULL
stimulation	NULL
;	NULL
the	NULL
observed	NULL
cell	NULL
type	NULL
specificity	NULL
argues	NULL
for	NULL
some	NULL
differences	NULL
,	NULL
however	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
putative	NULL
leucine	NULL
zipper	NULL
motif	NULL
in	NULL
the	NULL
C-terminal	NULL
domain	NULL
is	NULL
not	NULL
required	NULL
for	NULL
this	NULL
interaction	NULL
with	NULL
the	NULL
presumed	NULL
target	NULL
proteins	NULL
.	NULL

The	NULL
Oct2	NULL
C-terminal	NULL
domain	NULL
can	NULL
not	NULL
be	NULL
functionally	NULL
replaced	NULL
by	NULL
the	NULL
Oct1	NULL
C	NULL
terminus	NULL
.	NULL

It	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
failure	NULL
of	NULL
Oct1	NULL
to	NULL
activate	NULL
from	NULL
a	NULL
distance	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
is	NULL
merely	NULL
due	NULL
to	NULL
a	NULL
quantitative	NULL
difference	NULL
.	NULL

When	NULL
Octl	NULL
and	NULL
Oct2	NULL
were	NULL
assayed	NULL
for	NULL
promoter	NULL
stimulation	NULL
,	NULL
they	NULL
showed	NULL
almost	NULL
comparable	NULL
activities	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
qualitative	NULL
difference	NULL
between	NULL
the	NULL
Oct1	NULL
and	NULL
Oct2	NULL
C-terminal	NULL
domains	NULL
was	NULL
recently	NULL
also	NULL
described	NULL
with	NULL
respect	NULL
to	NULL
activation	NULL
of	NULL
small	NULL
nuclear	NULL
RNA	NULL
gene	NULL
promoters	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Strikingly	NULL
,	NULL
the	NULL
Oct2.5	NULL
isoform	NULL
,	NULL
which	NULL
was	NULL
weak	NULL
in	NULL
the	NULL
enhancer	NULL
activation	NULL
assay	NULL
,	NULL
behaved	NULL
similarly	NULL
to	NULL
Octl	NULL
in	NULL
these	NULL
studies	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
essential	NULL
region	NULL
for	NULL
enhancer	NULL
transactivation	NULL
is	NULL
localized	NULL
in	NULL
the	NULL
C-terminal	NULL
60	NULL
amino	NULL
acids	NULL
.	NULL

This	NULL
whole	NULL
region	NULL
seems	NULL
to	NULL
be	NULL
required	NULL
to	NULL
retain	NULL
full	NULL
activity	NULL
because	NULL
both	NULL
C-terminal	NULL
and	NULL
internal	NULL
deletions	NULL
led	NULL
to	NULL
partial	NULL
reduction	NULL
of	NULL
the	NULL
activity	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
the	NULL
sequence	NULL
requirements	NULL
for	NULL
promoter	NULL
and	NULL
enhancer	NULL
transactivation	NULL
are	NULL
clearly	NULL
different	NULL
.	NULL

A	NULL
potential	NULL
explanation	NULL
could	NULL
be	NULL
that	NULL
there	NULL
are	NULL
two	NULL
different	NULL
cofactors	NULL
that	NULL
interact	NULL
with	NULL
this	NULL
domain	NULL
and	NULL
mediate	NULL
enhancing	NULL
activity	NULL
.	NULL

Alternatively	NULL
,	NULL
a	NULL
single	NULL
factor	NULL
interacts	NULL
with	NULL
the	NULL
whole	NULL
domain	NULL
but	NULL
does	NULL
so	NULL
less	NULL
efficiently	NULL
if	NULL
part	NULL
of	NULL
the	NULL
domain	NULL
is	NULL
missing	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
the	NULL
extreme	NULL
C	NULL
terminus	NULL
of	NULL
Oct2	NULL
is	NULL
essential	NULL
for	NULL
enhancer	NULL
stimulation	NULL
provides	NULL
an	NULL
explanation	NULL
for	NULL
the	NULL
weak	NULL
activation	NULL
by	NULL
the	NULL
Oct2.5	NULL
isoform	NULL
.	NULL

In	NULL
this	NULL
isoform	NULL
,	NULL
the	NULL
final	NULL
12	NULL
amino	NULL
acids	NULL
are	NULL
replaced	NULL
by	NULL
a	NULL
novel	NULL
protein	NULL
sequence	NULL
due	NULL
to	NULL
an	NULL
alternate	NULL
splicing	NULL
event	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
Oct2	NULL
C	NULL
terminus	NULL
might	NULL
not	NULL
be	NULL
the	NULL
``	NULL
docking	NULL
site	NULL
``	NULL
``	NULL
for	NULL
a	NULL
specific	NULL
coactivator	NULL
,	NULL
but	NULL
rather	NULL
this	NULL
domain	NULL
might	NULL
be	NULL
required	NULL
for	NULL
proper	NULL
modification	NULL
or	NULL
conformation	NULL
of	NULL
the	NULL
Oct2	NULL
protein	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
Oct2	NULL
phosphorylation	NULL
state	NULL
has	NULL
revealed	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
Oct2	NULL
C	NULL
terminus	NULL
for	NULL
correct	NULL
phosphorylation	NULL
(	NULL
40	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
this	NULL
modification	NULL
correlated	NULL
with	NULL
efficient	NULL
transactivation	NULL
of	NULL
an	NULL
octamer-containing	NULL
promoter	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
not	NULL
unlikely	NULL
that	NULL
this	NULL
phosphorylation	NULL
is	NULL
also	NULL
crucial	NULL
for	NULL
the	NULL
function	NULL
of	NULL
Oct2	NULL
as	NULL
an	NULL
enhancer	NULL
factor	NULL
.	NULL

The	NULL
C	NULL
terminus	NULL
of	NULL
Oct2	NULL
could	NULL
specify	NULL
correct	NULL
phosphorylation	NULL
,	NULL
and	NULL
this	NULL
modification	NULL
in	NULL
turn	NULL
might	NULL
be	NULL
required	NULL
for	NULL
interaction	NULL
with	NULL
a	NULL
specific	NULL
coacti-vator	NULL
.	NULL

A	NULL
candidate	NULL
domain	NULL
for	NULL
protein-protein	NULL
interactions	NULL
is	NULL
the	NULL
POU	NULL
domain	NULL
.	NULL

Our	NULL
results	NULL
do	NULL
in	NULL
fact	NULL
indicate	NULL
that	NULL
the	NULL
Oct2	NULL
POU	NULL
domain	NULL
directly	NULL
affects	NULL
enhancer	NULL
transactivation	NULL
prop-erties	NULL
.	NULL

The	NULL
hybrid	NULL
protein	NULL
carrying	NULL
both	NULL
Oct2	NULL
N-	NULL
and	NULL
C-terminal	NULL
domains	NULL
and	NULL
the	NULL
POU	NULL
domain	NULL
of	NULL
Octl	NULL
could	NULL
not	NULL
stimulate	NULL
the	NULL
enhancer	NULL
as	NULL
efficiently	NULL
as	NULL
the	NULL
intact	NULL
Oct2	NULL
protein	NULL
.	NULL

Clear	NULL
differences	NULL
between	NULL
the	NULL
two	NULL
POU	NULL
domains	NULL
with	NULL
respect	NULL
to	NULL
interaction	NULL
with	NULL
the	NULL
VP16	NULL
transactivator	NULL
have	NULL
been	NULL
documented	NULL
(	NULL
36	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
conceivable	NULL
that	NULL
the	NULL
interaction	NULL
between	NULL
Oct2	NULL
and	NULL
the	NULL
putative	NULL
coactivator	NULL
involves	NULL
the	NULL
POU	NULL
domain	NULL
.	NULL

Transcriptional	NULL
activation	NULL
from	NULL
a	NULL
distance	NULL
by	NULL
a	NULL
glutamine-rich	NULL
domain	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
for	NULL
the	NULL
Spl	NULL
protein	NULL
(	NULL
2	NULL
)	NULL
.	NULL

For	NULL
Oct2	NULL
,	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
N-terminal	NULL
transactivation	NULL
domain	NULL
is	NULL
obvious	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Oct2	NULL
C	NULL
terminus	NULL
.	NULL

Most	NULL
interestingly	NULL
,	NULL
the	NULL
differences	NULL
between	NULL
Oct2.3	NULL
,	NULL
the	NULL
weakest	NULL
transactivator	NULL
,	NULL
and	NULL
the	NULL
strongly	NULL
stimulating	NULL
Oct2.6	NULL
isoform	NULL
are	NULL
confined	NULL
to	NULL
the	NULL
N	NULL
terminus	NULL
.	NULL

The	NULL
alterations	NULL
do	NULL
not	NULL
,	NULL
however	NULL
,	NULL
map	NULL
to	NULL
the	NULL
described	NULL
glutamine-rich	NULL
transactivation	NULL
domain	NULL
but	NULL
rather	NULL
are	NULL
localized	NULL
just	NULL
upstream	NULL
of	NULL
it	NULL
.	NULL

When	NULL
these	NULL
two	NULL
isoforms	NULL
are	NULL
compared	NULL
in	NULL
terms	NULL
of	NULL
their	NULL
respective	NULL
transactivation	NULL
potentials	NULL
on	NULL
octamer-containing	NULL
promoters	NULL
in	NULL
the	NULL
B-cell	NULL
line	NULL
,	NULL
essentially	NULL
the	NULL
same	NULL
difference	NULL
is	NULL
observed	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Previous	NULL
deletion	NULL
mapping	NULL
experiments	NULL
had	NULL
shown	NULL
that	NULL
removal	NULL
of	NULL
the	NULL
first	NULL
100	NULL
amino	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
acids	NULL
increased	NULL
the	NULL
promoter	NULL
transactivating	NULL
potential	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
supporting	NULL
the	NULL
idea	NULL
that	NULL
the	NULL
domain	NULL
upstream	NULL
of	NULL
the	NULL
glutamine-rich	NULL
transactivation	NULL
domain	NULL
has	NULL
a	NULL
regulatory	NULL
function	NULL
(	NULL
25	NULL
)	NULL
.	NULL

From	NULL
our	NULL
results	NULL
it	NULL
is	NULL
evident	NULL
that	NULL
the	NULL
two	NULL
Oct2	NULL
transactivation	NULL
domains	NULL
show	NULL
clear	NULL
functional	NULL
differences	NULL
when	NULL
assayed	NULL
for	NULL
promoter	NULL
and	NULL
enhancer	NULL
transactivation	NULL
.	NULL

With	NULL
respect	NULL
to	NULL
the	NULL
concept	NULL
of	NULL
transcriptional	NULL
coactivators	NULL
,	NULL
it	NULL
could	NULL
be	NULL
speculated	NULL
that	NULL
there	NULL
are	NULL
distinct	NULL
sets	NULL
of	NULL
adaptors	NULL
that	NULL
mediate	NULL
interactions	NULL
with	NULL
proximal	NULL
and	NULL
distal	NULL
transacti-vators	NULL
.	NULL

The	NULL
glutamine-rich	NULL
transactivation	NULL
domain	NULL
might	NULL
need	NULL
to	NULL
be	NULL
in	NULL
the	NULL
proximity	NULL
of	NULL
the	NULL
promoter	NULL
region	NULL
in	NULL
order	NULL
to	NULL
interact	NULL
with	NULL
probably	NULL
ubiquitous	NULL
adaptor	NULL
proteins	NULL
.	NULL

However	NULL
,	NULL
transactivation	NULL
domains	NULL
that	NULL
can	NULL
mediate	NULL
long-range	NULL
enhancement	NULL
,	NULL
such	NULL
as	NULL
acidic	NULL
domains	NULL
or	NULL
the	NULL
Oct2	NULL
C	NULL
termi-nus	NULL
,	NULL
might	NULL
be	NULL
capable	NULL
of	NULL
communicating	NULL
with	NULL
the	NULL
proximal	NULL
promoter	NULL
via	NULL
specialized	NULL
bridging	NULL
factors	NULL
.	NULL

The	NULL
identification	NULL
and	NULL
characterization	NULL
of	NULL
these	NULL
proteins	NULL
should	NULL
further	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
gene	NULL
regula-tion	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
K.	NULL
Seipel	NULL
and	NULL
W.	NULL
Schaffner	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
and	NULL
helpful	NULL
comments	NULL
on	NULL
the	NULL
manuscript	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
thank	NULL
W.	NULL
Herr	NULL
for	NULL
generously	NULL
providing	NULL
the	NULL
Octl-Oct2	NULL
fusion	NULL
constructs	NULL
;	NULL
T.	NULL
Gerster	NULL
for	NULL
the	NULL
Oct2	NULL
C-terminal	NULL
deletion	NULL
series	NULL
;	NULL
A.	NULL
Hecht	NULL
for	NULL
the	NULL
luciferase	NULL
reporters	NULL
;	NULL
S.	NULL
McKnight	NULL
for	NULL
the	NULL
murine	NULL
sarcoma	NULL
virus	NULL
VP16	NULL
plasmid	NULL
;	NULL
R.	NULL
Renkawitz	NULL
and	NULL
G.	NULL
Q.	NULL
Daley	NULL
for	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
and	NULL
pGD	NULL
expression	NULL
vectors	NULL
,	NULL
respectively	NULL
;	NULL
and	NULL
G.	NULL
Schiitz	NULL
and	NULL
A.	NULL
Leutz	NULL
for	NULL
B-galactosidase	NULL
reporter	NULL
plasmids	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
B.	NULL
Oeler	NULL
and	NULL
S.	NULL
Wegehingel	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
(	NULL
0316001A	NULL
)	NULL
from	NULL
the	NULL
Bundesministerium	NULL
fiir	NULL
Forschung	NULL
und	NULL
Technologie	NULL
.	NULL

A.A.	NULL
is	NULL
the	NULL
recipient	NULL
of	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Stiftung	NULL
Stipendien	NULL
Fonds	NULL
des	NULL
Verbands	NULL
der	NULL
Chemischen	NULL
Industrie	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Annweiler	NULL
,	NULL
A.	NULL
,	NULL
U.	NULL
Miller	NULL
,	NULL
and	NULL
T.	NULL
Wirth	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
defined	NULL
mutatins	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

20:1503-1509	NULL
.	NULL

1la.Clerc	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
L.	NULL
M.	NULL
Corcoran	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
B-cell-specific	NULL
Oct-2	NULL
protein	NULL
contains	NULL
POU	NULL
box-	NULL
and	NULL
homeo	NULL
box-type	NULL
domains	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:1570-1581	NULL
.	NULL

2	NULL
.	NULL

Courey	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
D.	NULL
A.	NULL
Holtzman	NULL
,	NULL
S.	NULL
P.	NULL
Jackson	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1989	NULL
.	NULL

Synergistic	NULL
activation	NULL
by	NULL
the	NULL
glutamine-rich	NULL
domains	NULL
of	NULL
human	NULL
transcription	NULL
factor	NULL
Spl	NULL
.	NULL

Cell	NULL
59:827-836	NULL
.	NULL

3	NULL
.	NULL

Currie	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
octamer-binding	NULL
site	NULL
in	NULL
the	NULL
mouse	NULL
kappa	NULL
light-chain	NULL
immunoglobulin	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:4239-4247	NULL
.	NULL

4	NULL
.	NULL

Daley	NULL
,	NULL
G.	NULL
Q.	NULL
,	NULL
R.	NULL
A	NULL
.	NULL

Van	NULL
Etten	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1990	NULL
.	NULL

Induction	NULL
of	NULL
chronic	NULL
myelogenous	NULL
leukemia	NULL
in	NULL
mice	NULL
by	NULL
the	NULL
p210	NULL
ber/abl	NULL
gene	NULL
of	NULL
the	NULL
Philadelphia	NULL
chromosome	NULL
.	NULL

Science	NULL
247:824-830	NULL
.	NULL

5.	NULL
de	NULL
Wet	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
K.	NULL
V.	NULL
Wood	NULL
,	NULL
M.	NULL
DeLuca	NULL
,	NULL
D.	NULL
R.	NULL
Helinski	NULL
,	NULL
and	NULL
S.	NULL
Subramani	NULL
.	NULL

1987	NULL
.	NULL

Firefly	NULL
luciferase	NULL
gene	NULL
:	NULL
structure	NULL
and	NULL
expression	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:725-737	NULL
.	NULL

6	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

7	NULL
.	NULL

Falkner	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Zachau	NULL
.	NULL

1984	NULL
.	NULL

Correct	NULL
transcription	NULL
of	NULL
an	NULL
immunoglobulin	NULL
k	NULL
gene	NULL
requires	NULL
an	NULL
upstream	NULL
fragment	NULL
containing	NULL
conserved	NULL
sequence	NULL
elements	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
310:71-74	NULL
.	NULL

8	NULL
.	NULL

Forsberg	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
G.	NULL
Westin	NULL
.	NULL

1991	NULL
.	NULL

Enhancer	NULL
activation	NULL
by	NULL
a	NULL
single	NULL
type	NULL
of	NULL
transcription	NULL
factor	NULL
shows	NULL
cell	NULL
type	NULL
dependence	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:2543-2551	NULL
.	NULL

9	NULL
.	NULL

Gerster	NULL
,	NULL
T.	NULL
,	NULL
C.-G.	NULL
Balmaceda	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
cell	NULL
type-specific	NULL
octamer	NULL
transcription	NULL
factor	NULL
OTF-2	NULL
has	NULL
two	NULL
do	NULL
Oct2	NULL
TRANSACTIVATION	NULL
AND	NULL
B-CELL-RESTRICTED	NULL
ACTIVITY	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

3115	NULL
mains	NULL
required	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:1635-1643	NULL
.	NULL

Gerster	NULL
,	NULL
T.	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.	NULL
Thali	NULL
,	NULL
J.	NULL
Jirieny	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1987	NULL
.	NULL

Cell	NULL
type-specificity	NULL
elements	NULL
of	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
gene	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:1323-1330	NULL
.	NULL

Giri	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
M.	NULL
Yaniv	NULL
.	NULL

1988	NULL
.	NULL

Structural	NULL
and	NULL
mutational	NULL
analysis	NULL
of	NULL
E2	NULL
trans-activating	NULL
proteins	NULL
of	NULL
papillomaviruses	NULL
reveals	NULL
three	NULL
distinct	NULL
functional	NULL
domains	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:2823-2829	NULL
.	NULL

Ham	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
Dostatni	NULL
,	NULL
F.	NULL
Arnos	NULL
,	NULL
and	NULL
M.	NULL
Yaniv	NULL
.	NULL

1991	NULL
.	NULL

Several	NULL
different	NULL
upstream	NULL
promoter	NULL
elements	NULL
can	NULL
potentiate	NULL
transactivation	NULL
by	NULL
the	NULL
BPV-1	NULL
E2	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:2931-2940	NULL
.	NULL

Hen	NULL
,	NULL
R.	NULL
,	NULL
E.	NULL
Borrelli	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1985	NULL
.	NULL

Repression	NULL
of	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
by	NULL
the	NULL
adenovirus-2	NULL
ElA	NULL
products	NULL
.	NULL

Science	NULL
230:1391-1394	NULL
.	NULL

Herbomel	NULL
,	NULL
P.	NULL
,	NULL
B.	NULL
Bourachot	NULL
,	NULL
and	NULL
M.	NULL
Yaniv	NULL
.	NULL

1984	NULL
.	NULL

Two	NULL
distinct	NULL
enhancers	NULL
with	NULL
different	NULL
cell	NULL
specificities	NULL
coexist	NULL
in	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
polyoma	NULL
.	NULL

Cell	NULL
39:653-662	NULL
.	NULL

Hermanson	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
M.	NULL
Briskin	NULL
,	NULL
D.	NULL
Sigman	NULL
,	NULL
and	NULL
R.	NULL
Wall	NULL
.	NULL

1989	NULL
.	NULL

Immunoglobulin	NULL
enhancer	NULL
and	NULL
promoter	NULL
motifs	NULL
5Â°	NULL
of	NULL
the	NULL
B29	NULL
B-cell-specific	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:7341-7345	NULL
.	NULL

Herr	NULL
,	NULL
W.	NULL
,	NULL
R.	NULL
A.	NULL
Sturm	NULL
,	NULL
R.	NULL
G.	NULL
Clerc	NULL
,	NULL
L.	NULL
M.	NULL
Corcoran	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
H.	NULL
A.	NULL
Ingraham	NULL
,	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
,	NULL
M.	NULL
Finney	NULL
,	NULL
G.	NULL
Ruvkun	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
Horvitz	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
POU	NULL
domain	NULL
:	NULL
a	NULL
large	NULL
conserved	NULL
region	NULL
in	NULL
the	NULL
mammalian	NULL
pit-1	NULL
,	NULL
oct-1	NULL
,	NULL
oct-2	NULL
,	NULL
and	NULL
Caenorhabditis	NULL
elegans	NULL
unc-86	NULL
gene	NULL
products	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:1513-1516	NULL
.	NULL

Junker	NULL
,	NULL
S.	NULL
,	NULL
S.	NULL
Pedersen	NULL
,	NULL
E.	NULL
Schreiber	NULL
,	NULL
and	NULL
P.	NULL
Matthias	NULL
.	NULL

1990	NULL
.	NULL

Extinction	NULL
of	NULL
an	NULL
immunoglobulin	NULL
x	NULL
promoter	NULL
in	NULL
cell	NULL
hybrids	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
octamer	NULL
motif	NULL
and	NULL
correlates	NULL
with	NULL
suppression	NULL
of	NULL
Oct-2	NULL
expression	NULL
.	NULL

Cell	NULL
61:467-474	NULL
.	NULL

Kemler	NULL
,	NULL
I.	NULL
,	NULL
E.	NULL
Bucher	NULL
,	NULL
K.	NULL
Seipel	NULL
,	NULL
M.	NULL
M.	NULL
Muller-Immergliick	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1991	NULL
.	NULL

Promoters	NULL
with	NULL
the	NULL
octamer	NULL
DNA	NULL
motif	NULL
{	NULL
(	NULL
ATGCAAAT	NULL
)	NULL
can	NULL
be	NULL
ubiquitous	NULL
or	NULL
cell	NULL
type-specific	NULL
depending	NULL
on	NULL
binding	NULL
affinity	NULL
of	NULL
the	NULL
octamer	NULL
site	NULL
and	NULL
Oct-factor	NULL
concentra-tion	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:237-242	NULL
.	NULL

LaBella	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
L.	NULL
Sive	NULL
,	NULL
R.	NULL
G.	NULL
Roeder	NULL
,	NULL
and	NULL
N.	NULL
Heintz	NULL
.	NULL

1988	NULL
.	NULL

Cell-cycle	NULL
regulation	NULL
of	NULL
a	NULL
human	NULL
histone	NULL
H2b	NULL
gene	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
H2b	NULL
subtype-specific	NULL
consensus	NULL
element	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:32-39	NULL
.	NULL

Landolfi	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
J.	NULL
D.	NULL
Capra	NULL
,	NULL
and	NULL
P.	NULL
W.	NULL
Tucker	NULL
.	NULL

1986	NULL
.	NULL

Interaction	NULL
of	NULL
cell-type-specific	NULL
nuclear	NULL
proteins	NULL
with	NULL
immunoglobulin	NULL
V	NULL
,	NULL
,	NULL
promoter	NULL
region	NULL
sequences	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323:548-551	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
W.	NULL
Pierce	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

Protein-binding	NULL
sites	NULL
in	NULL
Ig	NULL
gene	NULL
enhancers	NULL
determine	NULL
transcriptional	NULL
activity	NULL
and	NULL
inducibility	NULL
.	NULL

Science	NULL
236:1573-1577	NULL
.	NULL

Lewin	NULL
,	NULL
B	NULL
.	NULL

1990	NULL
.	NULL

Commitment	NULL
and	NULL
activation	NULL
at	NULL
pol	NULL
II	NULL
promoters	NULL
:	NULL
a	NULL
tail	NULL
of	NULL
protein-protein	NULL
interactions	NULL
.	NULL

Cell	NULL
61:1161-1164	NULL
.	NULL

Mitchell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
in	NULL
mammalian	NULL
cells	NULL
by	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
.	NULL

Science	NULL
245:371-378	NULL
.	NULL

Miller	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
S.	NULL
Ruppert	NULL
,	NULL
W.	NULL
Schaffner	NULL
,	NULL
and	NULL
P.	NULL
Matthias	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
cloned	NULL
octamer	NULL
transcription	NULL
factor	NULL
stimulates	NULL
transcription	NULL
from	NULL
lymphoid-specific	NULL
promoters	NULL
in	NULL
non-B	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
336:544-551	NULL
.	NULL

Miiller-Immergliick	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
W.	NULL
Schaffner	NULL
,	NULL
and	NULL
P.	NULL
Matthias	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
factor	NULL
Oct-2A	NULL
contains	NULL
functionally	NULL
redundant	NULL
activating	NULL
domains	NULL
and	NULL
works	NULL
selectively	NULL
from	NULL
a	NULL
promoter	NULL
but	NULL
not	NULL
from	NULL
a	NULL
remote	NULL
enhancer	NULL
position	NULL
in	NULL
non-lymphoid	NULL
(	NULL
HeLa	NULL
)	NULL
cells	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:1625-1634	NULL
.	NULL

Nelms	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
B	NULL
.	NULL

Van	NULL
Ness	NULL
.	NULL

1990	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
octamer-binding	NULL
site	NULL
in	NULL
the	NULL
human	NULL
kappa	NULL
light-chain	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:3843-3846	NULL
.	NULL

Okamoto	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Okazawa	NULL
,	NULL
A.	NULL
Okuda	NULL
,	NULL
M.	NULL
Sakai	NULL
,	NULL
M.	NULL
Mura-matsu	NULL
,	NULL
and	NULL
H.	NULL
Hamada	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
novel	NULL
octamer	NULL
binding	NULL
transcription	NULL
factor	NULL
is	NULL
differentially	NULL
expressed	NULL
in	NULL
mouse	NULL
embryonic	NULL
cells	NULL
.	NULL

Cell	NULL
60:461-472	NULL
.	NULL

Pellet	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
J.	NULL
L.	NULL
C.	NULL
McKnight	NULL
,	NULL
F.	NULL
J.	NULL
Jenkins	NULL
,	NULL
and	NULL
B.	NULL
Roizman	NULL
.	NULL

1985	NULL
.	NULL

Nucleotide	NULL
sequence	NULL
and	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
a	NULL
protein	NULL
encoded	NULL
in	NULL
a	NULL
small	NULL
herpes	NULL
simplex	NULL
virus	NULL
DNA	NULL
fragment	NULL
capable	NULL
of	NULL
trans-inducing	NULL
a	NULL
genes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:5870-5874	NULL
.	NULL

Pettersson	NULL
,	NULL
S.	NULL
,	NULL
G.	NULL
P.	NULL
Cook	NULL
,	NULL
M.	NULL
Briiggemann	NULL
,	NULL
G.	NULL
T.	NULL
Williams	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Neuberger	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
second	NULL
B	NULL
cell-specific	NULL
enhancer	NULL
3	NULL
'	NULL
of	NULL
3116	NULL
30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

ANNWEILER	NULL
ET	NULL
AL	NULL
.	NULL

the	NULL
immunoglobulin	NULL
heavy-chain	NULL
locus	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
344	NULL
:	NULL
165-168	NULL
.	NULL

Schatt	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
S.	NULL
Rusconi	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
.	NULL

1990	NULL
.	NULL

A	NULL
single	NULL
DNA-binding	NULL
transcription	NULL
factor	NULL
is	NULL
sufficient	NULL
for	NULL
activation	NULL
from	NULL
a	NULL
distant	NULL
enhancer	NULL
and/or	NULL
from	NULL
a	NULL
promoter	NULL
position	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:481-487	NULL
.	NULL

Scheidereit	NULL
,	NULL
C.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Cromlish	NULL
,	NULL
T.	NULL
Gerster	NULL
,	NULL
K.	NULL
Kawakami	NULL
,	NULL
C.-G.	NULL
Balmaceda	NULL
,	NULL
R.	NULL
A.	NULL
Currie	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
human	NULL
lymphoid-specific	NULL
transcription	NULL
factor	NULL
that	NULL
activates	NULL
immunoglobulin	NULL
genes	NULL
is	NULL
a	NULL
homoeobox	NULL
protein	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
336	NULL
:	NULL
551-557	NULL
.	NULL

Scholer	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
T.	NULL
Ciesiolka	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
nexus	NULL
between	NULL
Oct-4	NULL
and	NULL
ElA	NULL
:	NULL
implications	NULL
for	NULL
gene	NULL
regulation	NULL
in	NULL
embryonic	NULL
stem	NULL
cells	NULL
.	NULL

Cell	NULL
66:291-304	NULL
.	NULL

Sorger	NULL
,	NULL
P.	NULL
K.	NULL
,	NULL
and	NULL
H.	NULL
R.	NULL
B.	NULL
Pelham	NULL
.	NULL

1988	NULL
.	NULL

Yeast	NULL
heat	NULL
shock	NULL
factor	NULL
is	NULL
an	NULL
essential	NULL
DNA-binding	NULL
protein	NULL
that	NULL
exhibits	NULL
temper-ature-dependent	NULL
phosphorylation	NULL
.	NULL

Cell	NULL
54:855-864	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
R.	NULL
G.	NULL
Clerc	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Cloning	NULL
of	NULL
a	NULL
lymphoid-specific	NULL
cDNA	NULL
encoding	NULL
a	NULL
protein	NULL
binding	NULL
the	NULL
regulatory	NULL
octamer	NULL
DNA	NULL
motif	NULL
.	NULL

Science	NULL
241:577-580	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
lymphoid-specific	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323	NULL
:	NULL
640-643	NULL
.	NULL

Stern	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Tanaka	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Oct-l	NULL
home-odomain	NULL
directs	NULL
formation	NULL
of	NULL
a	NULL
multiprotein-DNA	NULL
complex	NULL
with	NULL
the	NULL
HSV	NULL
transactivator	NULL
VP16	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
341:624-630	NULL
.	NULL

Sterneck	NULL
,	NULL
E.	NULL
,	NULL
C.	NULL
Miller	NULL
,	NULL
S.	NULL
Katz	NULL
,	NULL
and	NULL
A.	NULL
Leutz	NULL
.	NULL

1992	NULL
.	NULL

Autocrine	NULL
growth	NULL
induced	NULL
by	NULL
kinase	NULL
type	NULL
oncogenes	NULL
in	NULL
myeloid	NULL
cells	NULL
requires	NULL
AP-1	NULL
and	NULL
NF-M	NULL
,	NULL
a	NULL
myeloid	NULL
specific	NULL
,	NULL
C/EBP	NULL
-like	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:115-126	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bror	NULL
.	NULL

Sturm	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
G.	NULL
Das	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
ubiquitous	NULL
octamer-binding	NULL
protein	NULL
Oct-1	NULL
contains	NULL
a	NULL
POU	NULL
domain	NULL
with	NULL
a	NULL
homeo	NULL
box	NULL
subdomain	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:1582-1599	NULL
.	NULL

Suzuki	NULL
,	NULL
N.	NULL
,	NULL
H.	NULL
Rohdewohld	NULL
,	NULL
T.	NULL
Neuman	NULL
,	NULL
P.	NULL
Gruss	NULL
,	NULL
and	NULL
H.	NULL
Scholer	NULL
.	NULL

1990	NULL
.	NULL

Oct-6	NULL
:	NULL
a	NULL
POU	NULL
transcription	NULL
factor	NULL
expressed	NULL
in	NULL
embryonal	NULL
stem	NULL
cells	NULL
and	NULL
in	NULL
the	NULL
developing	NULL
brain	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:3723-3732	NULL
.	NULL

Tanaka	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1990	NULL
.	NULL

Differential	NULL
transcriptional	NULL
activation	NULL
by	NULL
Oct-l	NULL
and	NULL
Oct-2	NULL
:	NULL
interdependent	NULL
activation	NULL
domains	NULL
induce	NULL
Oct-2	NULL
phosphorylation	NULL
.	NULL

Cell	NULL
60:375-386	NULL
.	NULL

Tanaka	NULL
,	NULL
M.	NULL
,	NULL
J.-S.	NULL
Lai	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1992	NULL
.	NULL

Promoter-selective	NULL
activation	NULL
domains	NULL
in	NULL
Oct-1	NULL
and	NULL
Oct-2	NULL
direct	NULL
differential	NULL
activation	NULL
of	NULL
an	NULL
snRNA	NULL
and	NULL
mRNA	NULL
promoter	NULL
.	NULL

Cell	NULL
68:755-767	NULL
.	NULL

Wirth	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Nuclear	NULL
factor	NULL
NF-	NULL
Â«	NULL
B	NULL
can	NULL
interact	NULL
functionally	NULL
with	NULL
its	NULL
cognate	NULL
binding	NULL
site	NULL
to	NULL
provide	NULL
lymphoid-specific	NULL
promoter	NULL
function	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:3109-3113	NULL
.	NULL

Wirth	NULL
,	NULL
T.	NULL
,	NULL
A.	NULL
Priess	NULL
,	NULL
A.	NULL
Annweiler	NULL
,	NULL
S.	NULL
Zwilling	NULL
,	NULL
and	NULL
B.	NULL
Ocler	NULL
.	NULL

1991	NULL
.	NULL

Multiple	NULL
Oct2	NULL
isoforms	NULL
are	NULL
generated	NULL
by	NULL
alternative	NULL
splic-ing	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:43-51.	NULL
.	NULL

Wirth	NULL
,	NULL
T.	NULL
,	NULL
L.	NULL
Staudt	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
octamer	NULL
oligonucleotide	NULL
upstream	NULL
of	NULL
a	NULL
TATA	NULL
motif	NULL
is	NULL
sufficient	NULL
for	NULL
lymphoid-specific	NULL
promoter	NULL
activity	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
329:174-178	NULL
.	NULL

Yamamoto	NULL
,	NULL
K.	NULL
K.	NULL
,	NULL
G.	NULL
A.	NULL
Gonzales	NULL
,	NULL
W.	NULL
H.	NULL
Biggs	NULL
III	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Montminy	NULL
.	NULL

1988	NULL
.	NULL

Phosphorylation-induced	NULL
binding	NULL
and	NULL
transcriptional	NULL
efficacy	NULL
of	NULL
nuclear	NULL
factor	NULL
CREB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
334:494-498	NULL
.	NULL

Yu	NULL
,	NULL
H.	NULL
,	NULL
B.	NULL
Porton	NULL
,	NULL
L.	NULL
Shen	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Eckhardt	NULL
.	NULL

1989	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
octamer	NULL
motif	NULL
in	NULL
hybrid	NULL
cell	NULL
extinction	NULL
of	NULL
immunoglobulin	NULL
expression	NULL
:	NULL
extinction	NULL
is	NULL
dominant	NULL
in	NULL
a	NULL
two	NULL
enhancer	NULL
system	NULL
.	NULL

Cell	NULL
58:441-448	NULL
.	NULL

Zwilling	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
T.	NULL
Wirth	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

